Exporter

You can select particular sections to be included in the output file.
EN
FR

Liste modèle des médicaments essentiels

Trouvé 1300 recommandations pour 634 médicaments et 133 équivalents thérapeutiques
Les recommandations supprimées et les demandes rejetées sont affichées. Les cacher.
  1. BCG vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tuberculosis
  2. Japanese encephalitis vaccine Informations générales
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  3. Medicines for COVID-19 Informations générales
    Section
    Medicines for COVID-19
    • Refer to WHO living guidelines
    Indications
    COVID-19
  4. Abacavir Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (as sulfate)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  5. Abacavir + lamivudine Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  6. Abacavir + lamivudine + lopinavir + ritonavir Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  7. Abemaciclib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to palbociclib pour Other specified malignant neoplasms of breast
  8. Abiraterone Informations générales
    Section
    Hormones and antihormones
    • Oral > Solid: 250 mg; 500 mg
    Indications
    Malignant neoplasms of prostate
  9. Acamprosate calcium Informations générales
    Section
    Medicines for alcohol use disorders
    • Oral > Solid > tablet: 333 mg
    Indications
    Disorders due to use of alcohol
  10. Acetazolamide Informations générales
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Oral > Solid: 250 mg
    Indications
    Primary open-angle glaucoma
  11. Acetic acid Informations générales
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 2% in alcohol
    Indications
    Infectious diseases of external ear
  12. Acetylcysteine Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule
    • Oral > Liquid: 10%; 20%
    Indications
    Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs Acute or subacute hepatic failure
  13. Acetylsalicylic acid Informations générales
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Solid: 300 to 500 mg
    Indications
    Migraine
    Section
    Anti-platelet medicines
    • Oral > Solid: 100 mg
    Indications
    Acute myocardial infarction Cerebral ischaemic stroke
    Section
    Medicines for juvenile joint diseases
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 50 to 150 mg
    Indications
    Acute rheumatic fever without mention of heart involvement Mucocutaneous lymph node syndrome Juvenile idiopathic arthritis
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 50 to 150 mg
    Indications
    Pain
  14. Acetylsalicylic acid + atorvastatin + ramipril Informations générales
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 40 mg + 5 mg; 100 mg + 40 mg + 10 mg
    Indications
    Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke
  15. Acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide Informations générales
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg
    Indications
    Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke
  16. Aciclovir Informations générales
    Section
    Antiherpes medicines
    • Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet
    Indications
    Zoster Varicella Herpes simplex infections
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 3% w/w
    Indications
    Herpes simplex keratitis
  17. Aclidinium Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide pour Chronic obstructive pulmonary disease
  18. Activated charcoal Informations générales
    Section
    Antidotes and other substances used in poisonings > Non-specific
    • Oral > Other: powder
    Indications
    Unspecified injury, poisoning or certain other consequences of external causes
  19. Adalimumab Informations générales
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Axial spondyloarthritis Crohn disease site Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Juvenile idiopathic arthritis
  20. Afatinib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung
  21. Albendazole Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 400 mg (chewable, scored)
    • Oral > Solid > tablet: 400 mg (chewable, scored))
    Indications
    Echinococcosis Ascariasis Enterobiasis Trichuriasis Hookworm diseases Cysticercosis
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)
    Indications
    Other specified echinococcosis Cysticercosis of central nervous system
    Section
    Antifilarials
    • Oral > Solid > tablet: 400 mg (chewable, scored)
    Indications
    Filariasis
  22. Alcohol based hand rub Informations générales
    Section
    Disinfectants
    • Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol
    Indications
    Denatured alcohol
  23. Alcuronium Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 5 mg per mL in 2 mL ampoule (alcuronium chloride)
    Indications
    Muscle relaxants
  24. Alfacalcidol Informations générales
    Section
    Medicines for endocrine disorders
    • Oral > Liquid: 2 µg per mL
    • Oral > Solid > capsule: 0.25 µg; 1 µg
    Indications
    Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport
  25. All-trans retinoic acid Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 10 mg capsule
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  26. Allopurinol Informations générales
    Section
    Medicines used to treat gout
    • Oral > Solid: 100 mg
    Indications
    Gout
    Section
    Supportive medicines
    • Oral > Solid: 100 mg; 300 mg
    Indications
    Tumour lysis syndrome
  27. Alteplase Informations générales
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection
    Indications
    Cerebral ischaemic stroke
  28. Amidotrizoate Informations générales
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)
    Indications
    Amidotrizoate
  29. Amikacin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis
    Section
    Antituberculosis medicines
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    Premier choix
    Neutropenia (high-risk) co-prescrite avec cefotaxime Acute pyelonephritis (severe) co-prescrite avec cefotaxime Inflammatory and other diseases of prostate (severe) co-prescrite avec ceftriaxone Acute pyelonephritis (severe) co-prescrite avec ceftriaxone Inflammatory and other diseases of prostate (severe)
    Second choix
    co-prescrite avec cloxacillin Sepsis without septic shock
  30. Amiloride Informations générales
    Section
    Diuretics
    • Oral > Solid: 5 mg (hydrochloride)
    Indications
    Oedema Ascites
  31. Amiodarone Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)
    Indications
    Cardiac arrhythmia
  32. Amitriptyline Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 25 mg; 10 mg; 75 mg
    Indications
    Palliative care
    Section
    Medicines for depressive disorders
    • Oral > Solid: 25 mg; 75 mg
    Indications
    Depressive disorders
  33. Amlodipine Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 5 mg (as maleate, mesylate or besylate)
    Indications
    Essential hypertension
  34. Amodiaquine Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  35. Amodiaquine + sulfadoxine + pyrimethamine Informations générales
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package
    Indications
    Malaria
  36. Amoxicillin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet
    • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
    • Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
    • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
    • Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
    Indications
    Premier choix
    Acute sinusitis Acute otitis media Acute pharyngitis Acute malnutrition in infants, children or adolescents (complicated) [children] Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Chronic obstructive pulmonary disease with acute exacerbation Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) co-prescrite avec gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec gentamicin Sepsis without septic shock
    Second choix
    Bacterial meningitis
    Autres indications
    Bacterial infection of unspecified site Infectious cystitis
  37. Amoxicillin + clavulanic acid Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    • Oral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid
    • Oral > Solid: 500 mg + 125 mg tablet
    • Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
    • Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
    • Oral > Liquid: 125 mg + 31.25 mg powder for oral liquid; 250 mg + 62.5 mg powder for oral liquid
    Indications
    Premier choix
    Peritoneal abscess (mild-moderate) Neutropenia (low-risk) Bacterial cellulitis, erysipelas or lymphangitis Acute sinusitis Peritonitis (mild-moderate) Infectious cystitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Chronic obstructive pulmonary disease with acute exacerbation
    Second choix
    Other specified prophylactic measures Acute otitis media Osteomyelitis or osteitis Bacterial infection of joint Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) co-prescrite avec clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe)
    Autres indications
    Bacterial infection of unspecified site
    Section
    Antituberculosis medicines
    • Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  38. Amphotericin B Informations générales
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
    Indications
    Blastomycosis Cryptococcosis Candidosis Coccidioidomycosis Histoplasmosis Sporotrichosis Aspergillosis
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
    Indications
    Visceral leishmaniasis
  39. Ampicillin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
    • Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)
    Indications
    Premier choix
    co-prescrite avec gentamicin Peritoneal abscess (severe) co-prescrite avec gentamicin Sepsis without septic shock co-prescrite avec gentamicin Peritoneal abscess (mild-moderate) co-prescrite avec gentamicin Peritonitis (severe) co-prescrite avec gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec gentamicin Peritonitis (mild-moderate) co-prescrite avec gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choix
    Bacterial meningitis
    Autres indications
    Bacterial infection of unspecified site
  40. Anakinra Informations générales
    Section
    Medicines for juvenile joint diseases
    • Parenteral > General injections > SC: 100 mg per 0.67 mL in pre-filled syringe
    Indications
    Juvenile systemic arthritis
  41. Anastrozole Informations générales
    Section
    Hormones and antihormones
    • Oral > Solid: 1 mg tablet
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast
  42. Anidulafungin Informations générales
    Section
    Antifungal medicines
    Indications
    Therapeutic equivalent to micafungin pour Systemic or invasive candidosis
  43. Ansuvimab Informations générales
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 400 mg powder for injection
    Indications
    Ebola virus disease
  44. Anti-d immunoglobulin Informations générales
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 250 µg in single-dose vial
    • Parenteral > General injections > IM: 250 µg in single-dose vial
    Indications
    Maternal care for red cell antibodies Rh incompatibility reaction
  45. Anti-rabies immunoglobulin Informations générales
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 150 IU per mL in vial
    • Parenteral > Locoregional injections > Other: 150 IU per mL in vial
    Indications
    Rabies
  46. Anti-rabies virus monoclonal antibodies Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)
    Indications
    Rabies
  47. Anti-tetanus immunoglobulin Informations générales
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 500 IU in vial
    Indications
    Tetanus
  48. Antirabies hyperimmune serum Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > unspecified: 1000 IU in 5 mL ampoule
    Indications
    Rabies
  49. Antivenom immunoglobulin Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IV:
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  50. Antivenom sera Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IV:
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  51. Apixaban Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran pour Venous thromboembolism Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation
  52. Aprepitant Informations générales
    Section
    Antiemetic medicines
    • Oral > Liquid: 125 mg powder for oral suspension (in sachet)
    • Oral > Solid: 80 mg; 125 mg; 165 mg
    Indications
    Nausea or vomiting
  53. Aripiprazole Informations générales
    Section
    Medicines for psychotic disorders
    Indications
    Therapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders
  54. Arsenic trioxide Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  55. Artemether Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IM: 80 mg per mL in 1 mL ampoule (oily injection)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  56. Artemether + lumefantrine Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  57. Artesunate Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution
    • Oral > Solid: 50 mg tablet
    • Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  58. Artesunate + amodiaquine Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  59. Artesunate + mefloquine Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  60. Artesunate + pyronaridine tetraphosphate Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  61. Ascorbic acid Informations générales
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
    Scurvy
  62. Asparaginase Informations générales
    Section
    Cytotoxic medicines
    • Powder for injection: 10 000 IU in vial.
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified
  63. Atazanavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  64. Atazanavir + ritonavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  65. Atenolol Informations générales
    Section
    Antianginal medicines
    • Oral > Solid: 50 mg; 100 mg
    Indications
    Angina pectoris
    Section
    Antihypertensive medicines
    • Oral > Solid: 50 mg; 100 mg
    Indications
    Essential hypertension Therapeutic equivalent to bisoprolol pour Essential hypertension
  66. Atezolizumab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion
    Indications
    Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab pour Other specified malignant neoplasms of bronchus or lung
  67. Atoltivimab + maftivimab + odesivimab Informations générales
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial
    Indications
    Ebola virus disease
  68. Atorvastatin Informations générales
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis
  69. Atorvastatin + perindopril + amlodipine Informations générales
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 20 mg + 5 mg + 5 mg; 20 mg + 10 mg + 10 mg; 40 mg + 5 mg + 5 mg; 40 mg + 10 mg + 10 mg
    Indications
    Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke
  70. Atracurium Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL (besylate)
    Indications
    Muscle relaxants Therapeutic equivalent to vecuronium pour Muscle relaxants
  71. Atropine Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
    Indications
    Exposure to or harmful effects of undetermined intent of pesticides
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
    Indications
    Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics
    Section
    Diagnostic agents > Ophthalmic medicines
    Indications
    Therapeutic equivalent to tropicamide pour Cycloplegic drug
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)
    Indications
    Anterior uveitis
  72. Axicabtagene ciloleucel Informations générales
    Section
    Antineoplastics and supportive medicines
    • Cell suspension for infusion: 2 × 10*6 anti-CD19 CAR-positive viable T-cells per kg of body weight.
    Indications
    Diffuse large B-cell lymphomas
  73. Azacitidine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection
    Indications
    Myeloid leukaemia
  74. Azathioprine Informations générales
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 50 mg
    Indications
    Rheumatoid arthritis, serology unspecified Psoriatic arthritis
    Section
    Immunomodulators for non-malignant disease
    • Oral > Solid: 50 mg
    • Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt); 50 mg in vial powder for injection (as sodium salt)
    • Oral > Liquid: 10 mg per mL
    • Oral > Solid > tablet: 50 mg (scored); 25 mg
    Indications
    Relapsing-remitting multiple sclerosis Failure or rejection of transplanted organs or tissues
  75. Azithromycin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 1.5% eye drops
    Indications
    Trachoma
    Section
    Watch group antibiotics
    • Oral > Liquid: 200 mg per 5 mL oral liquid
    • Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule
    • Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)
    • Oral > Solid > dosage form: 500 mg (anhydrous); 250 mg (anhydrous)
    Indications
    Premier choix
    Typhoid fever Trachoma Chlamydia trachomatis Yaws Paratyphoid fever co-prescrite avec ceftriaxone Gonococcal infection
    Second choix
    Infectious gastroenteritis or colitis without specification of infectious agent co-prescrite avec cefixime Gonococcal infection
  76. Aztreonam Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection
    Indications
    Other specified bacterial diseases
  77. Barium sulfate Informations générales
    Section
    Diagnostic agents > Radiocontrast media
    • Oral > Liquid: Aqueous suspension
    Indications
    Barium sulfate with suspending agents
  78. Beclometasone Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)
    Indications
    Therapeutic equivalent to budesonide pour Asthma Asthma
  79. Beclometasone + formoterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol pour Asthma
  80. Bedaquiline Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg tablet; 20 mg tablet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  81. Bendamustine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma
  82. Benzathine benzylpenicillin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)
    Indications
    Premier choix
    Syphilis Congenital syphilis [children]
    Autres indications
    Bacterial infection of unspecified site
  83. Benznidazole Informations générales
    Section
    American trypanosomiasis
    • Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg
    Indications
    Chagas disease
  84. Benzoic acid + salicylic acid Informations générales
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Cream: 6% + 3%
    • Local > Topical > Ointment: 6% + 3%
    Indications
    Fungal infection of the skin
  85. Benzoyl peroxide Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 5%
    • Local > Topical > Lotion: 5%
    Indications
    Acne
  86. Benzyl benzoate Informations générales
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Lotion: 25%
    Indications
    Pthiriasis Pediculosis corporis Pediculosis capitis Scabies
  87. Benzylpenicillin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)
    Indications
    Premier choix
    Congenital syphilis [children] Syphilis co-prescrite avec gentamicin Sepsis without septic shock co-prescrite avec gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choix
    Bacterial meningitis
    Autres indications
    Bacterial infection of unspecified site
  88. Betamethasone Informations générales
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 0.1% (as valerate)
    • Local > Topical > Ointment: 0.1% (as valerate)
    Indications
    Pruritus due to skin disorder Psoriasis of unspecified type Dermatitis or eczema Lichen planus
  89. Bevacizumab Informations générales
    Section
    Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
    • Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
    Indications
    Age related macular degeneration
  90. Bicalutamide Informations générales
    Section
    Hormones and antihormones
    • Oral > Solid: 50 mg
    Indications
    Malignant neoplasms of prostate
  91. Binimetinib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to trametinib pour Other specified melanoma of skin
  92. Biperiden Informations générales
    Section
    Medicines for parkinsonism
    • Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)
    • Oral > Solid: 2 mg tablet (hydrochloride)
    Indications
    Parkinson disease
  93. Bisacodyl Informations générales
    Section
    Laxatives
    Indications
    Therapeutic equivalent to senna pour Constipation
  94. Bisoprolol Informations générales
    Section
    Antianginal medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Angina pectoris
    Section
    Medicines used in heart failure
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Heart failure
    Section
    Antihypertensive medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Essential hypertension
    Section
    Antiarrhythmic medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Cardiac arrhythmia
  95. Bleomycin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
    • Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Kaposi sarcoma of unspecified primary site Hodgkin lymphoma Other specified malignant neoplasms of the ovary Germ cell tumour of testis
  96. Bortezomib Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
    Indications
    Plasma cell myeloma
  97. Bromocriptine Informations générales
    Section
    Antiseizure medicines
    • Oral > Solid: 2.5 mg; 5 mg
    Indications
    Parkinson disease
    Section
    Medicines for disorders of the pituitary hormone system
    Indications
    Therapeutic equivalent to cabergoline pour Other specified benign neoplasm of endocrine glands
  98. Budesonide Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 100 µg per dose; 200 µg per dose
    Indications
    Asthma
    Section
    Ear, nose and throat medicines [c]
    • Local > Nasal > Spray: 100 µg per dose
    Indications
    Allergic rhinitis
  99. Budesonide + formoterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose
    Indications
    Asthma
  100. Budesonide + salmeterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol pour Asthma
  101. Bumetanide Informations générales
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to furosemide pour Heart failure
    Section
    Diuretics
    Indications
    Therapeutic equivalent to furosemide pour Anuria or oliguria Therapeutic equivalent to furosemide pour Oedema
  102. Bupivacaine Informations générales
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution
    • Parenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)
    Indications
    Local anaesthetics
  103. Buprenorphine Informations générales
    Section
    Medicines for opioid use disorders
    Indications
    Therapeutic equivalent to methadone pour Opioid dependence
  104. Bupropion Informations générales
    Section
    Medicines for nicotine use disorders
    • Oral > Solid: 150 mg sustained-release (hydrochloride)
    Indications
    Nicotine dependence
  105. C1 esterase inhibitor Informations générales
    Section
    Plasma-derived medicines
    • Parenteral > General injections > IV: 500 IU in vial powder for injection
    Indications
    Hereditary angioedema
  106. Cabergoline Informations générales
    Section
    Antiseizure medicines
    • Oral > Solid: 0.5 mg
    Indications
    Parkinson disease
    Section
    Medicines for disorders of the pituitary hormone system
    • Oral > Solid > tablet: 0.5 mg; 1 mg
    Indications
    Other specified benign neoplasm of endocrine glands
  107. Caffeine citrate Informations générales
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
    • Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
    Indications
    Apnoea of newborn
  108. Calamine Informations générales
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Lotion:
    Indications
    Pruritus
  109. Calcipotriol Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 50 µg per mL (0.005%)
    • Local > Topical > Lotion: 50 µg per mL (0.005%)
    • Local > Topical > Ointment: 50 µg per mL (0.005%)
    Indications
    Psoriasis of unspecified type
  110. Calcitriol Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to calcipotriol pour Psoriasis of unspecified type
    Section
    Medicines for endocrine disorders
    • Oral > Solid > capsule: 0.25 µg; 0.5 µg
    Indications
    Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport
  111. Calcium Informations générales
    Section
    Vitamins and minerals
    • Oral > Solid: 500 mg (elemental calcium)
    Indications
    Calcium deficiency
  112. Calcium folinate (leucovorin calcium) Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 15 mg tablet
    • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule
    • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Solid > tablet: 15 mg; 5 mg; 25 mg
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasm metastasis in large intestine Malignant trophoblastic neoplasms of placenta Burkitt lymphoma including Burkitt leukaemia Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of rectum Malignant neoplasms of colon
  113. Calcium gluconate Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Hypermagnesaemia
    Section
    Vitamins and minerals
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Tetany due to acute calcium deficiency
  114. Canagliflozin Informations générales
    Section
    Oral hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin pour Type 2 diabetes mellitus
  116. Capreomycin Informations générales
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1000 mg powder for injection (vial)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  117. Captopril Informations générales
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg
    Indications
    Heart failure
  118. Carbachol Informations générales
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    Indications
    Therapeutic equivalent to pilocarpine pour Acute angle closure with pupillary block Therapeutic equivalent to pilocarpine pour Ocular hypertension Therapeutic equivalent to pilocarpine pour Primary open-angle glaucoma
  119. Carbamazepine Informations générales
    Section
    Antiseizure medicines
    • Oral > Liquid: 100 mg per 5 mL
    • Oral > Solid > tablet: 200 mg (scored); 100 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)
    Indications
    Epilepsy or seizures
    Section
    Medicines for bipolar disorders
    • Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg
    Indications
    Bipolar or related disorders
  120. Carbetocin Informations générales
    Section
    Uterotonics
    • Parenteral > General injections > IV: 100 µg per mL (heat stable)
    Indications
    Postpartum haemorrhage
  121. Carbimazole Informations générales
    Section
    Thyroid hormones and antithyroid medicines
    Indications
    Therapeutic equivalent to methimazole pour Thyrotoxicosis
  123. Carmellose Informations générales
    Section
    Ophthalmological preparations
    Indications
    Therapeutic equivalent to hypromellose pour Keratoconjunctivitis sicca
  124. Carvedilol Informations générales
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Angina pectoris
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol pour Heart failure
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Essential hypertension
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Cardiac arrhythmia
  125. Caspofungin Informations générales
    Section
    Antifungal medicines
    Indications
    Therapeutic equivalent to micafungin pour Systemic or invasive candidosis
  126. Cefalexin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid: 250 mg (as monohydrate)
    • Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
    • Oral > Solid > dispersible tablet: 125 mg; 250 mg
    Indications
    Premier choix
    Bacterial cellulitis, erysipelas or lymphangitis
    Second choix
    Acute pharyngitis Chronic obstructive pulmonary disease with acute exacerbation
    Autres indications
    Bacterial infection of unspecified site
  127. Cefazolin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
    Indications
    Premier choix
    Other specified prophylactic measures co-prescrite avec metronidazole Other specified prophylactic measures
    Second choix
    Osteomyelitis or osteitis Bacterial infection of joint
    Autres indications
    Surgical site infection
  128. Cefepime Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection
    Indications
    Other specified bacterial diseases
  129. Cefixime Informations générales
    Section
    Watch group antibiotics
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
    Indications
    Second choix
    Infectious gastroenteritis or colitis without specification of infectious agent co-prescrite avec azithromycin Gonococcal infection
  130. Cefotaxime Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    Indications
    Premier choix
    Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis co-prescrite avec amikacin Inflammatory and other diseases of prostate (severe) co-prescrite avec amikacin Acute pyelonephritis (severe) co-prescrite avec clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) co-prescrite avec metronidazole Peritonitis (mild-moderate) co-prescrite avec metronidazole Peritonitis (severe) co-prescrite avec metronidazole Peritoneal abscess (severe)
    Second choix
    Acute pyelonephritis (mild to moderate) Osteomyelitis or osteitis Bacterial infection of joint Sepsis without septic shock Inflammatory and other diseases of prostate (mild to moderate)
    Autres indications
    Bacterial infection of unspecified site
  131. Ceftaroline Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection
    Indications
    Other specified bacterial diseases
  132. Ceftazidime Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
    Indications
    Premier choix
    co-prescrite avec vancomycin Endophthalmitis
    Autres indications
    Pseudomonas aeruginosa resistant to other antibiotic
  133. Ceftazidime + avibactam Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  134. Ceftolozane + tazobactam Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g + 0.5 g powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa
  135. Ceftriaxone Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 2 g in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    Indications
    Premier choix
    Other specified pneumonia (Hospital-acquired pneumonia) Paratyphoid fever Typhoid fever Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Bacterial meningitis co-prescrite avec amikacin Inflammatory and other diseases of prostate (severe) co-prescrite avec amikacin Acute pyelonephritis (severe) co-prescrite avec azithromycin Gonococcal infection co-prescrite avec clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec metronidazole Peritonitis (severe) co-prescrite avec metronidazole Peritonitis (mild-moderate) co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) co-prescrite avec metronidazole Necrotising fasciitis co-prescrite avec metronidazole Peritoneal abscess (severe) co-prescrite avec vancomycin Endophthalmitis
    Second choix
    Acute pyelonephritis (mild to moderate) Osteomyelitis or osteitis Inflammatory and other diseases of prostate (mild to moderate) Bacterial infection of joint Sepsis without septic shock Infectious gastroenteritis or colitis without specification of infectious agent
    Autres indications
    Bacterial infection of unspecified site
  136. Cefuroxime Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
    Indications
    Second choix
    Other specified prophylactic measures
  137. Cemiplimab Informations générales
    Section
    Immunomodulators
    Indications
    Therapeutic equivalent to pembrolizumab pour Other specified malignant neoplasms of bronchus or lung
  138. Certolizumab pegol Informations générales
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
  139. Cetirizine Informations générales
    Section
    Antiallergics and medicines used in anaphylaxis
    Indications
    Therapeutic equivalent to loratadine pour Allergic or hypersensitivity conditions of unspecified type
  141. Chloramphenicol Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
    • Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
    • Oral > Liquid: 150 mg per 5 mL (as palmitate)
    • Oral > Solid: 250 mg capsule
    Indications
    Second choix
    Bacterial meningitis
    Autres indications
    Bacterial infection of unspecified site
  142. Chlorhexidine Informations générales
    Section
    Medicines administered to the neonate [c]
    • Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    • Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    Indications
    Omphalitis of newborn
    Section
    Antiseptics
    • Local > Topical > Solution: 5% (digluconate) for dilution
    Indications
    Chlorhexidine
  143. Chlorine base compound Informations générales
    Section
    Disinfectants
    • Local > Topical > Powder: 0.1% available chlorine for solution
    • Local > Topical > Liquid: 0.1% available chlorine for solution
    • Local > Topical > Solid: 0.1% available chlorine for solution
    Indications
    Disinfectant, not elsewhere classified
  144. Chloroquine Informations générales
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
    • Oral > Solid: 150 mg tablet (as phosphate or sulfate)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax Malaria due to Plasmodium ovale Malaria due to Plasmodium malariae
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)
    • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
    • Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)
    Indications
    Rheumatoid arthritis
  145. Chlorothiazide Informations générales
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Essential hypertension
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Heart failure
  146. Chloroxylenol Informations générales
    Section
    Disinfectants
    • Local > Topical > Solution: 4.8%
    Indications
    Phenol disinfectant, not elsewhere classified
  147. Chlorpromazine Informations générales
    Section
    Medicines for psychotic disorders
    • Oral > Liquid: 25 mg per 5 mL (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride)
    Indications
    Schizophrenia or other primary psychotic disorders Therapeutic equivalent to haloperidol pour Schizophrenia or other primary psychotic disorders
  148. Chlortalidone Informations générales
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Essential hypertension
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Heart failure
  149. Chlortetracycline Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to tetracycline pour Other specified conjunctivitis Therapeutic equivalent to tetracycline pour Infectious keratitis Therapeutic equivalent to tetracycline pour Infectious blepharitis Therapeutic equivalent to tetracycline pour Trachoma
  150. Cholera vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against cholera alone
  151. Ciclesonide Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide pour Asthma
  152. Ciclosporin Informations générales
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
    • Oral > Liquid: 100 mg per mL
    • Oral > Solid > capsule: 25 mg
    Indications
    Failure or rejection of transplanted organs or tissues
  153. Cimetidine Informations générales
    Section
    Antiulcer medicines
    • Oral > Solid: 200 mg
    • Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule
    Indications
    Peptic ulcer, site unspecified Gastro-oesophageal reflux disease
  154. Ciprofloxacin Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL (as hyclate)
    • Oral > Liquid: 250 mg per 5 mL (anhydrous)
    • Oral > Solid: 250 mg (as hydrochloride)
    • Oral > Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)
    • Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
    Indications
    Premier choix
    Paratyphoid fever Typhoid fever Acute pyelonephritis (mild to moderate) Neutropenia (low-risk) Infectious gastroenteritis or colitis without specification of infectious agent Inflammatory and other diseases of prostate (mild to moderate)
    Second choix
    Cholera [children] Cholera co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) co-prescrite avec metronidazole Peritonitis (mild-moderate)
    Autres indications
    Bacterial infection of unspecified site
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 0.3% (as hydrochloride)
    Indications
    Infectious diseases of external ear
  156. Cladribine Informations générales
    Section
    Medicines for multiple sclerosis
    • Oral > Solid > tablet: 10 mg
    Indications
    Multiple sclerosis
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial
    Indications
    Langerhans cell histiocytosis
  157. Clarithromycin Informations générales
    Section
    Watch group antibiotics
    • Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
    • Oral > Solid > dosage form: 500 mg; 250 mg
    • Oral > Solid: 500 mg
    Indications
    Premier choix
    co-prescrite avec cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe)
    Second choix
    Acute pharyngitis co-prescrite avec amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe)
  158. Clindamycin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride) capsule
    • Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
    • Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
    • Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride)
    Indications
    Premier choix
    co-prescrite avec piperacillin + tazobactam Necrotising fasciitis
    Second choix
    Osteomyelitis or osteitis Bacterial infection of joint
    Autres indications
    Bacterial infection of unspecified site
  159. Clofazimine Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg; 50 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg; 50 mg
    Indications
    Leprosy
  160. Clomifene Informations générales
    Section
    Ovulation inducers
    • Oral > Solid: 50 mg (citrate)
    Indications
    Female infertility without specification whether primary or secondary
  161. Clomipramine Informations générales
    Section
    Medicines for obsessive compulsive disorders
    • Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
    Indications
    Obsessive-compulsive disorder
  162. Clonazepam Informations générales
    Section
    Antiseizure medicines
    • Oral > Solid: 500 µg
    Indications
    Generalised myoclonic seizure
  163. Clopidogrel Informations générales
    Section
    Anti-platelet medicines
    • Oral > Solid: 75 mg; 300 mg
    Indications
    Acute ischaemic heart disease Presence of coronary angioplasty implant or graft
  164. Clotrimazole Informations générales
    Section
    Antifungal medicines
    • Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet
    Indications
    Vulvovaginal candidosis
  165. Cloxacillin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
    • Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
    • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
    • Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)
    Indications
    Premier choix
    Bacterial cellulitis, erysipelas or lymphangitis Bacterial infection of joint Osteomyelitis or osteitis
    Second choix
    co-prescrite avec amikacin Sepsis without septic shock
    Autres indications
    Bacterial infection of unspecified site
  166. Clozapine Informations générales
    Section
    Medicines for psychotic disorders
    • Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg
    Indications
    Schizophrenia or other primary psychotic disorders
  167. Coagulation factor IX Informations générales
    Section
    Blood coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
    Coagulation defects, purpura or other haemorrhagic or related conditions Haemophilia B
  168. Coagulation factor IX complex Informations générales
    Section
    Blood coagulation factors
    Indications
    Therapeutic equivalent to coagulation factor IX pour Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to coagulation factor IX pour Haemophilia B
  169. Coagulation factor VIII Informations générales
    Section
    Blood coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection; 250 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
    Haemophilia A
  170. Coal tar Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 5%
    Indications
    Psoriasis of unspecified type
  171. Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  172. Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  173. Cobimetinib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to trametinib pour Other specified melanoma of skin
  174. Codeine Informations générales
    Section
    Opioid analgesics
    • Oral > Solid: 30 mg tablet (codeine phosphate)
    Indications
    Pain
    Section
    Antitussives
    • Oral > Solid: 10 mg tablet (codeine phosphate)
    Indications
    Cough
    Section
    Medicines for diarrhoea
    • Oral > Solid: 30 mg tablet (codeine phosphate)
    Indications
    Diarrhoea
  175. Colchicine Informations générales
    Section
    Medicines used to treat gout
    • Oral > Solid: 0.5 mg
    Indications
    Gout
  176. Colecalciferol Informations générales
    Section
    Vitamins and minerals
    • Oral > Liquid: 400 IU per mL
    • Oral > Solid: 400 IU; 1000 IU
    Indications
    Calcium deficiency Vitamin D deficiency Therapeutic equivalent to ergocalciferol pour Vitamin D deficiency Therapeutic equivalent to ergocalciferol pour Calcium deficiency
  177. Colistin (injection) Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)
    Indications
    Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  178. Compound sodium lactate solution Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: injectable solution
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance Hypovolaemic shock
  180. Copper-containing intrauterine device Informations générales
    Section
    Intrauterine devices
    • -
    Indications
    Contact with health services for insertion of contraceptive device
  181. Crizotinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 200 mg; 250 mg
    • Oral > Solid > capsule: 200 mg; 250 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung Anaplastic large cell lymphoma, ALK-positive
  182. Cryoprecipitate (pathogen-reduced) Informations générales
    Section
    Blood and blood components
    • Injection: frozen liquid in bag or lyophilized powder in vial containing:
    • > 50 IU Factor VIII
    • > 100 IU vWF
    • > 140 mg clottable fibrinogen per unit
    Indications
    Coagulation defects, purpura or other haemorrhagic or related conditions Von Willebrand disease Obstetric haemorrhage
  183. Cyanocobalamin Informations générales
    Section
    Antianaemia medicines
    • .
    Indications
    Anaemias or other erythrocyte disorders
  184. Cyclizine Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 50 mg tablet
    • Parenteral > General injections > unspecified: 50 mg per mL
    Indications
    Palliative care
  185. Cyclopentolate Informations générales
    Section
    Diagnostic agents > Ophthalmic medicines
    Indications
    Therapeutic equivalent to tropicamide pour Cycloplegic drug
    Section
    Ophthalmological preparations > Mydriatics
    Indications
    Therapeutic equivalent to atropine pour Anterior uveitis
  186. Cyclophosphamide Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 25 mg tablet
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    • Oral > Solid: 25 mg; 50 mg
    • Oral > Solid: 25 mg; 50 mg tablet
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of breast Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Other specified gliomas of brain Other specified malignant neoplasms of breast Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site Hodgkin lymphoma Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive
  187. Cycloserine Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg; 125 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  189. Dabigatran Informations générales
    Section
    Medicines affecting coagulation
    • Oral > Solid: 110 mg; 150 mg
    Indications
    Venous thromboembolism Other specified atrial fibrillation
  190. Dabrafenib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 50 mg; 75 mg
    Indications
    Other specified melanoma of skin
  191. Dacarbazine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection
    Indications
    Hodgkin lymphoma
  192. Daclatasvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)
    Indications
    Chronic hepatitis C
  193. Daclatasvir + sofosbuvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 60 mg + 400 mg
    Indications
    Chronic hepatitis C
  195. Dalteparin Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin pour Acute ischaemic heart disease Therapeutic equivalent to enoxaparin pour Venous thromboembolism
  196. Dapagliflozin Informations générales
    Section
    Oral hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin pour Type 2 diabetes mellitus
  197. Dapsone Informations générales
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet
    Indications
    Leprosy
  198. Daptomycin Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection
    Indications
    Other specified bacterial diseases
  199. Daratumumab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL
    Indications
    Plasma cell myeloma
  200. Darbepoetin alfa Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  201. Darunavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  202. Dasabuvir Informations générales
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 250 mg tablet
    Indications
    Chronic hepatitis C
  203. Dasatinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  204. Daunorubicin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
    Indications
    Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Acute myeloid leukaemia with recurrent genetic abnormalities
  205. Deferasirox Informations générales
    Section
    Other medicines for haemoglobinopathies
    • Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg
    • Oral > Solid > tablet: 90 mg; 180 mg; 360 mg
    Indications
    Therapeutic equivalent to deferoxamine pour Thalassaemias Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias
  206. Deferoxamine Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
    Indications
    Harmful effects of drugs, medicaments or biological substances, not elsewhere classified
    Section
    Other medicines for haemoglobinopathies
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
    Indications
    Thalassaemias Other specified sickle cell disorders or other haemoglobinopathies
  207. Delafloxacin Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 300 mg lyophilized powder for injection
    • Oral > Solid: 450 mg
    Indications
    Methicillin resistant Staphylococcus aureus
  208. Delamanid Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg tablet; 25 mg tablet (dispersible)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  209. Dengue vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  210. Desmopressin Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
    • Local > Nasal > Spray: 10 µg per dose (acetate)
    Indications
    Haemophilia A Von Willebrand disease
  211. Dexamethasone Informations générales
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))
    Indications
    Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy
    Section
    Hormones and antihormones
    • Oral > Solid: 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    Indications
    Plasma cell myeloma Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
    Indications
    Allergic or hypersensitivity conditions of unspecified type
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
    Indications
    Palliative care
    Section
    Antiemetic medicines
    • Oral > Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL
    • Oral > Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
    Indications
    Nausea or vomiting
  212. Dextran 40 Informations générales
    Section
    Plasma substitutes
    • .
    Indications
    Hypovolaemia
  213. Dextran 70 Informations générales
    Section
    Plasma substitutes
    • Parenteral > General injections > IV: 6% injectable solution
    Indications
    Hypovolaemia
  215. Diazepam Informations générales
    Section
    Antiseizure medicines
    • Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
    • Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
    Indications
    Therapeutic equivalent to lorazepam pour Status epilepticus Status epilepticus
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 5 mg; 10 mg
    • Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
    • Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
    • Parenteral > General injections > unspecified: 5 mg per mL
    Indications
    Palliative care
    Section
    Medicines for anxiety disorders
    • Oral > Solid: 5 mg (scored); 2 mg (scored)
    Indications
    Anxiety
  216. Diazoxide Informations générales
    Section
    Medicines for hypoglycaemia
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 50 mg
    Indications
    Persistent hyperinsulinaemic hypoglycaemia of infancy
  217. Didanosine Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
    • Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  218. Diethylcarbamazine Informations générales
    Section
    Antifilarials
    • Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)
    Indications
    Lymphatic filariasis
  219. Digitoxin Informations générales
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 0.2 mg in 1 mL ampoule
    • Oral > Solid: 50 µg; 100 µg
    Indications
    Heart failure
  220. Digoxin Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid: 62.5 µg; 250 µg
    Indications
    Cardiac arrhythmia
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg
    Indications
    Heart failure
  221. Dihydroartemisinin + piperaquine phosphate Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  222. Dihydroergocryptine mesylate Informations générales
    Section
    Antiseizure medicines
    • Oral > Solid:
    Indications
    Parkinson disease
  223. Diloxanide Informations générales
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Solid: 500 mg (furoate)
    Indications
    Amoebiasis
  224. Dimercaprol Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  225. Diphtheria antitoxin Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial
    Indications
    Need for immunization against diphtheria alone
  226. Diphtheria vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against diphtheria alone
  227. Diphtheria-pertussis-tetanus vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against diphtheria-tetanus-pertussis, combined
  228. Diphtheria-tetanus vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against combinations of infectious diseases
  230. Docusate sodium Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 50 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg capsule
    Indications
    Palliative care
  231. Dolasetron Informations générales
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron pour Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron pour Nausea or vomiting
  232. Dolutegravir Informations générales
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  233. Dolutegravir + lamivudine + tenofovir Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  234. Donepezil Informations générales
    Section
    Medicines for diseases of the nervous system
    • Oral > Liquid: 1 mg per mL (hydrochloride)
    • Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 5 mg (hydrochloride) (orodispersible); 10 mg (hydrochloride) (orodispersible)
    Indications
    Dementia due to Alzheimer disease
  235. Dopamine Informations générales
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)
    Indications
    Heart failure Cardiogenic shock
  236. Doxorubicin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    • Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Rhabdomyosarcoma primary site Follicular lymphoma Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of breast Lymphoid leukaemia, not elsewhere classified Other specified malignant neoplasms of breast Diffuse large B-cell lymphomas Plasma cell myeloma Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site Hodgkin lymphoma Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive
  237. Doxorubicin (as pegylated liposomal) Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    Indications
    Kaposi sarcoma of unspecified primary site
  238. Doxycycline Informations générales
    Section
    Access group antibiotics
    • Oral > Solid: 100 mg (as hyclate)
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection
    • Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
    • Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)
    • Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
    • Oral > Solid: 50 mg (as hyclate); 100 mg (as hyclate)
    • Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
    Indications
    Premier choix
    Cholera Chlamydia trachomatis
    Second choix
    Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Cholera [children] Chronic obstructive pulmonary disease with acute exacerbation
    Autres indications
    Bacterial infection of unspecified site
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)
    Indications
    Malaria due to Plasmodium falciparum
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 100 mg (hydrochloride or hyclate)
    Indications
    Malaria due to Plasmodium falciparum
  239. Durvalumab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 120 mg per 2.4 mL in vial; 500 mg per 10 mL in vial
    Indications
    Other specified malignant neoplasms of bronchus or lung
  240. Edoxaban Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran pour Venous thromboembolism Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation
  241. Efavirenz Informations générales
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Solid: 600 mg tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  242. Efavirenz + emtricitabine + tenofovir Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  243. Efavirenz + lamivudine + tenofovir Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to efavirenz + emtricitabine + tenofovir pour Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  244. Eflornithine Informations générales
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)
    Indications
    African trypanosomiasis
  245. Elbasvir + grazoprevir Informations générales
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 50 mg + 100 mg
    Indications
    Chronic hepatitis C
  246. Empagliflozin Informations générales
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 10 mg; 25 mg
    Indications
    Type 2 diabetes mellitus
  247. Emtricitabine Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 10 mg per mL
    • Oral > Solid: 200 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  248. Emtricitabine + rilpivirine + tenofovir alafenamide Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 25 mg + 25 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  249. Emtricitabine + rilpivirine + tenofovir disoproxil fumarate Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  250. Emtricitabine + tenofovir Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus
  251. Emtricitabine + tenofovir alafenamide Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  252. Enalapril Informations générales
    Section
    Antihypertensive medicines
    • Oral > Liquid: 1 mg per mL (as hydrogen maleate)
    • Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
    Indications
    Essential hypertension
    Section
    Medicines used in heart failure
    • Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
    Indications
    Heart failure
  253. Encorafenib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to dabrafenib pour Other specified melanoma of skin
  254. Enoxaparin Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 120 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
    Indications
    Acute ischaemic heart disease Venous thromboembolism
  255. Entecavir Informations générales
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 0.05 mg per mL
    • Oral > Solid: 0.5 mg; 1 mg
    Indications
    Chronic hepatitis B
  256. Enzalutamide Informations générales
    Section
    Hormones and antihormones
    • Oral > Solid: 40 mg
    Indications
    Therapeutic equivalent to abiraterone pour Malignant neoplasms of prostate Malignant neoplasms of prostate
  257. Ephedrine Informations générales
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)
    Indications
    Cardiac complications of anaesthesia during labour or delivery
  258. Epinephrine Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)
    Indications
    Cardiac arrest
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)
    Indications
    Primary open-angle glaucoma
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)
    Indications
    Asthma Chronic obstructive pulmonary disease
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)
    Indications
    Anaphylaxis
  259. Epoetin alfa Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  260. Epoetin beta Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  261. Epoetin theta Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  262. Equine rabies immunoglobulin Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial
    Indications
    Rabies
  263. Eravacycline Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 50 mg lyophilized powder for injection
    Indications
    Carbapenem resistant Enterobacterales
  264. Ergocalciferol Informations générales
    Section
    Vitamins and minerals
    • Oral > Liquid: 250 µg per mL (10 000 IU per mL)
    • Oral > Solid: 1.25 mg (50 000 IU)
    Indications
    Therapeutic equivalent to colecalciferol pour Calcium deficiency Therapeutic equivalent to colecalciferol pour Vitamin D deficiency Vitamin D deficiency Calcium deficiency
  265. Ergometrine Informations générales
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)
    Indications
    Postpartum haemorrhage
  266. Erlotinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung
  267. Erythromycin Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
    • Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
    • Oral > Solid: 250 mg (as stearate or ethylsuccinate)
    Indications
    Second choix
    Therapeutic equivalent to clarithromycin pour Acute pharyngitis
    Autres indications
    Bacterial infection of unspecified site
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 0.5%
    Indications
    Chlamydial conjunctivitis Gonococcal infection of eye
  268. Erythropoiesis-stimulating agents Informations générales
    Section
    Antianaemia medicines
    • Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
    Indications
    Anaemia due to chronic disease
  269. Estradiol Informations générales
    Section
    Estrogens
    • Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg
    Indications
    Hypopituitarism Gonadotropin deficiency Turner syndrome
  270. Estradiol cypionate + medroxyprogesterone acetate Informations générales
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 5 mg + 25 mg
    Indications
    Contact with health services for reasons associated with reproduction
  271. Etanercept Informations générales
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
  272. Ethambutol Informations générales
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
    • Oral > Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg tablet (dispersible)
    Indications
    Other specified tuberculosis Tuberculosis
  273. Ethambutol + isoniazid Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 400 mg + 150 mg tablet
    Indications
    Tuberculosis
  274. Ethambutol + isoniazid + pyrazinamide + rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet
    Indications
    Tuberculosis
  275. Ethambutol + isoniazid + rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 150 mg tablet
    Indications
    Tuberculosis
  276. Ethanol Informations générales
    Section
    Antiseptics
    • Local > Topical > Solution: 70% (denatured)
    Indications
    Denatured alcohol
  277. Ether Informations générales
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > solution:
    Indications
    Anaesthetics and therapeutic gases
  278. Ethinylestradiol + etonogestrel Informations générales
    Section
    Intravaginal contraceptives
    • Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg
    Indications
    Contact with health services for contraceptive management
  279. Ethinylestradiol + levonorgestrel Informations générales
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 50 µg + 250 µg [4]
    • Oral > Solid: 30 µg + 150 µg
    Indications
    Contact with health services for postcoital contraception Contact with health services for contraceptive management
  280. Ethinylestradiol + norethisterone Informations générales
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 35 µg + 1 mg
    Indications
    Contact with health services for contraceptive management
  281. Ethionamide Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg tablet; 125 mg tablet (dispersible)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis Tuberculous meningitis
  282. Ethosuximide Informations générales
    Section
    Antiseizure medicines
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid: 250 mg
    Indications
    Absence seizures, typical
  283. Etonogestrel-releasing implant Informations générales
    Section
    Implantable contraceptives
    • Implant > Subdermal: 68 mg single rod
    Indications
    Contact with health services for insertion of contraceptive device
  284. Etoposide Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
    • Oral > Solid: 100 mg capsule
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
    • Oral > Solid: 100 mg capsule; 50 mg capsule
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Hodgkin lymphoma Retinoblastoma Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive
  285. Everolimus Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 2 mg tablet (dispersible); 3 mg tablet (dispersible); 5 mg tablet (dispersible)
    Indications
    Other specified gliomas of brain
  286. Fentanyl Informations générales
    Section
    Opioid analgesics
    • Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
    • Oral > Solid: 100 to 800 µg sub-lingual tablet (as citrate); 200 to 1600 µg lozenge (as citrate)
    • Oral > Other: 200 to 1200 µg buccal film (as citrate)
    Indications
    Chronic cancer pain Other specified chronic cancer related pain
  287. Ferrous salt Informations générales
    Section
    Antianaemia medicines
    • Oral > Liquid: 25 mg per mL iron (as sulfate)
    • Oral > Solid: 60 mg iron
    Indications
    Iron deficiency anaemia
  288. Ferrous salt + folic acid Informations générales
    Section
    Antianaemia medicines
    • Oral > Solid: 60 mg iron + 2.8 mg
    • Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg
    Indications
    Iron deficiency anaemia Clefts of lip, alveolus or palate Iron deficiency anaemia Anencephaly or similar anomalies Spina bifida
  289. Fexinidazole Informations générales
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Oral > Solid: 600 mg
    Indications
    African trypanosomiasis
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid: 600 mg
    Indications
    African trypanosomiasis
  290. Fexofenadine Informations générales
    Section
    Antiallergics and medicines used in anaphylaxis
    Indications
    Therapeutic equivalent to loratadine pour Allergic or hypersensitivity conditions of unspecified type
  291. Fifth generation cephalosporins Informations générales
    Section
    Reserve group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  292. Filgrastim Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
    Indications
    Acquired neutropaenia
  293. Fingolimod Informations générales
    Section
    Immunomodulators for non-malignant disease
    • Oral > Solid: 0.25 mg; 0.5 mg
    Indications
    Relapsing-remitting multiple sclerosis
  294. Flomoxef Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection
    Indications
    Other specified other antibiotic resistant Enterobacterales
  295. Fluconazole Informations générales
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2 mg per mL in vial
    • Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid
    • Oral > Solid > capsule: 50 mg
    Indications
    Cryptococcosis Candidosis
  296. Flucytosine Informations générales
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2.5 g per 250 mL infusion
    • Oral > Solid: 250 mg capsule
    Indications
    Cryptococcosis
  297. Fludarabine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
    • Oral > Solid: 10 mg tablet (fludarabine phosphate)
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  298. Fludrocortisone Informations générales
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid: 100 µg (acetate)
    Indications
    Adrenocortical insufficiency
  299. Flunisolide Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide pour Asthma
  300. Fluorescein Informations générales
    Section
    Diagnostic agents > Ophthalmic medicines
    • Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)
    Indications
    Fluorescein
  301. Fluoride Informations générales
    Section
    Dental medicines and preparations
    • Local > Dental > Gel: 2500 to 12500 ppm fluoride (any type)
    • Local > Dental > Toothpaste, cream or gel: 1000 to 1500 ppm fluoride (any type)
    • Local > Dental > Mouthrinse: 230 to 900 ppm fluoride (any type)
    • Local > Dental > Varnish: 22500 ppm fluoride (any type)
    Indications
    Dental caries
  302. Fluorouracil Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Ointment: 5%
    Indications
    Plantar warts
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule
    • Parenteral > General injections > IV: 50 mg per mL in vial
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasms of nasopharynx Malignant neoplasm metastasis in large intestine Malignant neoplasms of breast Malignant neoplasms of rectum Malignant neoplasms of colon
  303. Fluoxetine Informations générales
    Section
    Medicines for depressive disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Depressive disorders
    Section
    Medicines for anxiety disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Social anxiety disorder Generalised anxiety disorder Panic disorder
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Palliative care
    Section
    Medicines for obsessive compulsive disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Obsessive-compulsive disorder
  304. Fluphenazine Informations générales
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)
    Indications
    Schizophrenia or other primary psychotic disorders
  305. Flutamide Informations générales
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide pour Malignant neoplasms of prostate
  306. Fluticasone Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide pour Asthma
  307. Fluticasone + formoterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol pour Asthma
  308. Fluticasone furoate + vilanterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol pour Asthma
  309. Fluvastatin Informations générales
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis
  310. Folic acid Informations générales
    Section
    Antianaemia medicines
    • Oral > Solid: 1 mg tablet; 5 mg tablet
    • Oral > Solid: 400 µg
    Indications
    Folate deficiency anaemia Anencephaly or similar anomalies Spina bifida Cephalocele
  311. Fomepizole Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule (sulfate); 1 g per mL in 1.5 mL ampoule (base)
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  312. Fosfomycin (injection) Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
    Indications
    Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  313. Fourth generation cephalosporins Informations générales
    Section
    Watch group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  314. Fresh-frozen plasma Informations générales
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  315. Fulvestrant Informations générales
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 250 mg per 5 mL
    Indications
    Malignant neoplasms of breast
  316. Furosemide Informations générales
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
    • Oral > Solid > tablet: 40 mg; 20 mg
    Indications
    Heart failure
    Section
    Diuretics
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
    • Oral > Solid > tablet: 40 mg; 20 mg
    Indications
    Anuria or oliguria Oedema
  317. Gabapentin Informations générales
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg
    Indications
    Neuropathic pain
  318. Gallamine Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 40 mg per mL in 2 mL ampoule (gallamine triethiodide)
    Indications
    Muscle relaxants
  319. Gatifloxacin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 200 mg; 400 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  320. Gefitinib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung
  321. Gemcitabine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
    Indications
    Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung
  322. Gentamicin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
    Indications
    Premier choix
    Neonatal meningitis co-prescrite avec amoxicillin Sepsis without septic shock co-prescrite avec amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin Peritoneal abscess (mild-moderate) co-prescrite avec ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin Peritoneal abscess (severe) co-prescrite avec ampicillin Peritonitis (severe) co-prescrite avec ampicillin Sepsis without septic shock co-prescrite avec ampicillin Peritonitis (mild-moderate) co-prescrite avec ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec benzylpenicillin Sepsis without septic shock
    Second choix
    Other specified prophylactic measures Gonococcal infection
    Autres indications
    Bacterial infection of unspecified site
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)
    Indications
    Other specified conjunctivitis Infectious blepharitis
  323. Glass ionomer cement Informations générales
    Section
    Dental medicines and preparations
    • Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid
    Indications
    Dental caries
  324. Glatiramer acetate Informations générales
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > SC: 20 mg per mL; 40 mg per mL
    • Parenteral > General injections > SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe
    Indications
    Relapsing-remitting multiple sclerosis Multiple sclerosis
  325. Glecaprevir + pibrentasvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 100 mg + 40 mg tablet; 50 mg + 20 mg granules
    Indications
    Chronic hepatitis C
  326. Glibenclamide Informations générales
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 5 mg; 2.5 mg
    Indications
    Type 2 diabetes mellitus
  327. Gliclazide Informations générales
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release
    Indications
    Type 2 diabetes mellitus
  328. Glucagon Informations générales
    Section
    Medicines for hypoglycaemia
    • Parenteral > General injections > unspecified: 1 mg per mL
    Indications
    Hypoglycaemia in the context of diabetes
  329. Glucose Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
    • Parenteral > General injections > IV: 50% hypertonic
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance Hypoglycaemia without associated diabetes
  330. Glucose + sodium chloride Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
  331. Glutaral Informations générales
    Section
    Disinfectants
    • Local > Topical > Solution: 2%
    Indications
    Glutaral nonmedicinal
  332. Glyceryl trinitrate Informations générales
    Section
    Antianginal medicines
    • Oral > Solid: 500 µg sublingual tablet
    Indications
    Angina pectoris
  333. Glycopyrronium Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide pour Chronic obstructive pulmonary disease
  334. Golimumab Informations générales
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
  335. Goserelin Informations générales
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin pour Malignant neoplasms of breast Therapeutic equivalent to leuprorelin pour Malignant neoplasms of prostate
  336. Granisetron Informations générales
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron pour Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron pour Nausea or vomiting
  337. Griseofulvin Informations générales
    Section
    Antifungal medicines
    • Oral > Liquid: 125 mg per 5 mL
    • Oral > Solid: 125 mg; 250 mg
    Indications
    Dermatophytosis
  338. Haemophilus influenzae type b vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  339. Haloperidol Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 0.5 mg; 2 mg; 5 mg
    • Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule
    Indications
    Palliative care
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 5 mg per mL in ampoule
    • Oral > Solid: 2 mg; 5 mg
    Indications
    Schizophrenia or other primary psychotic disorders
  340. Haloperidol decanoate Informations générales
    Section
    Medicines for psychotic disorders
    Indications
    Therapeutic equivalent to fluphenazine pour Schizophrenia or other primary psychotic disorders
  341. Halothane Informations générales
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > liquid:
    Indications
    Anaesthetics and therapeutic gases
  342. Heparin sodium Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 1000 IU per mL in 5 mL ampoule; 20000 IU per mL in 5 mL ampoule; 5000 IU per mL in 5 mL ampoule
    Indications
    Acute ischaemic heart disease Unstable angina Venous thromboembolism
  343. Hepatitis a vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  344. Hepatitis b vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  345. Homatropine Informations générales
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)
    Indications
    Anterior uveitis Therapeutic equivalent to atropine pour Anterior uveitis
  346. Human papilloma virus (HPV) vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  347. Hydralazine Informations générales
    Section
    Antihypertensive medicines
    • Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
    • Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)
    • Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)
    Indications
    Essential hypertension Gestational hypertension
  348. Hydrochlorothiazide Informations générales
    Section
    Antihypertensive medicines
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg; 12.5 mg
    Indications
    Essential hypertension
    Section
    Medicines used in heart failure
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg
    Indications
    Heart failure
    Section
    Diuretics
    • Oral > Solid: 25 mg
    Indications
    Oedema
  349. Hydrocortisone Informations générales
    Section
    Hormones and antihormones
    • Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
    Indications
    Lymphoid leukaemia, not elsewhere classified Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid: 5 mg; 10 mg; 20 mg
    Indications
    Adrenocortical insufficiency
    Section
    Ophthalmological preparations > Anti-inflammatory agents
    • Local > Ophthalmological > Ointment: 1% (acetate)
    Indications
    Scleritis Anterior uveitis
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)
    Indications
    Anaphylaxis
    Section
    Anti-inflammatory medicines
    • Local > Rectal > Suppository: 25 mg (acetate)
    • Local > Rectal > Retention enema: 100 mg per 60 mL
    Indications
    Crohn disease site Ulcerative colitis
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 1% (acetate)
    • Local > Topical > Ointment: 1% (acetate)
    Indications
    Dermatitis or eczema Lichen planus Pruritus due to skin disorder Psoriasis of unspecified type
  350. Hydromorphone Informations générales
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine pour Pain
  351. Hydroxocobalamin Informations générales
    Section
    Antianaemia medicines
    • Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)
    Indications
    Megaloblastic anaemia due to vitamin B12 deficiency
  352. Hydroxycarbamide (hydroxyurea) Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
    • Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
    Indications
    Squamous cell carcinoma of oropharynx Chronic myeloid leukaemia, not elsewhere classified
    Section
    Other medicines for haemoglobinopathies
    • Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies
  353. Hydroxychloroquine Informations générales
    Section
    Antimalarial medicines > For chemoprevention
    Indications
    Therapeutic equivalent to chloroquine pour Malaria due to Plasmodium falciparum
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 200 mg (as sulfate)
    Indications
    Systemic lupus erythematosus Cutaneous lupus erythematosus of unspecified type
  354. Hyoscine butylbromide Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > unspecified: 20 mg per mL injection
    Indications
    Palliative care
  355. Hyoscine hydrobromide Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch
    • Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection
    Indications
    Palliative care
  356. Hypochlorous acid Informations générales
    Section
    Antiseptics
    • Local > Topical > Solution:
    Indications
    Disinfectant, not elsewhere classified
  357. Hypromellose Informations générales
    Section
    Ophthalmological preparations
    • Local > Ophthalmological > Solution (eye drops): 0.3%
    Indications
    Keratoconjunctivitis sicca
  358. Ibrutinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 140 mg
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  359. Ibuprofen Informations générales
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 5 mg per mL
    Indications
    Patent arterial duct
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL
    • Oral > Solid > tablet: 200 mg; 400 mg; 600 mg
    Indications
    Pain
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL
    • Oral > Solid > tablet: 200 mg; 400 mg
    Indications
    Migraine
  360. Idoxuridine Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.1%
    • Local > Ophthalmological > Ointment: 0.2%
    Indications
    Herpes simplex keratitis
  361. Ifosfamide Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    • Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection
    Indications
    Other specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive
  363. Imipenem + cilastatin Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection
    Indications
    Second choix
    Therapeutic equivalent to meropenem pour Neutropenia (high-risk) Therapeutic equivalent to meropenem pour Peritoneal abscess (severe) Therapeutic equivalent to meropenem pour Peritonitis (severe)
    Autres indications
    Pseudomonas aeruginosa resistant to other antibiotic Antibiotic resistant Acinetobacter baumannii
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to meropenem pour Multi-drug resistant Mycobacterium tuberculosis
  364. Imipenem + cilastatin + relebactam Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection
    Indications
    Other specified other antibiotic resistant Enterobacterales Carbapenem resistant Enterobacterales Carbapenem-resistant Pseudomonas aeruginosa
  365. Indapamide Informations générales
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Essential hypertension
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Heart failure
  366. Indinavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 400 mg (as sulfate)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  367. Indometacin Informations générales
    Section
    Medicines administered to the neonate [c]
    Indications
    Therapeutic equivalent to ibuprofen pour Patent arterial duct
  368. Infliximab Informations générales
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
  369. Influenza vaccine (seasonal) Informations générales
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against influenza
  370. Insulin Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble); 100 IU per mL in 3 mL cartridge (soluble); 100 IU per mL in 3 mL pre-filled pen (soluble)
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble); 100 IU per mL in 3 mL cartridge (soluble); 100 IU per mL in 3 mL pre-filled pen
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  371. Insulin analogues Informations générales
    Section
    Insulins
    • Not specified
    Indications
    Type 1 diabetes mellitus Type 2 diabetes mellitus
  372. Insulin degludec Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 100 units per mL
    Indications
    Therapeutic equivalent to insulin glargine pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 2 diabetes mellitus
  373. Insulin detemir Informations générales
    Section
    Insulins
    Indications
    Therapeutic equivalent to insulin glargine pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 2 diabetes mellitus
  374. Insulin glargine Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 100 units per mL
    Indications
    Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 2 diabetes mellitus
  375. Intermediate-acting insulin Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin
    Indications
    Type 2 diabetes mellitus
  376. Intraperitoneal dialysis solution Informations générales
    Section
    Peritoneal dialysis solution
    • parenteral solution
    Indications
    Care involving peritoneal dialysis
  377. Iodine Informations générales
    Section
    Vitamins and minerals
    • Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule
    • Oral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle
    • Oral > Solid: 190 mg
    Indications
    Iodine deficiency
    Section
    Antiseptics
    Indications
    Therapeutic equivalent to povidone iodine pour Povidone iodine
  378. Iohexol Informations générales
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule
    Indications
    X-ray contrast media, iodinated
  379. Ipecacuanha Informations générales
    Section
    Antidotes and other substances used in poisonings > Non-specific
    • Oral > Liquid: 0.14% ipecacuanha alkaloids calculated as emetine
    Indications
    Unspecified injury, poisoning or certain other consequences of external causes
  380. Ipratropium bromide Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 20 µg per dose
    Indications
    Asthma Chronic obstructive pulmonary disease
  381. Irinotecan Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site
  382. Isoflurane Informations générales
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > liquid:
    Indications
    Anaesthetics and therapeutic gases
  383. Isoniazid Informations générales
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 100 mg per mL
    • Oral > Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet
    Indications
    Other specified tuberculosis Tuberculosis
  384. Isoniazid + pyrazinamide + rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible)
    Indications
    Tuberculosis
  385. Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim Informations générales
    Section
    Medicines for prevention of HIV-related opportunistic infections
    • Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)
    Indications
    Other specified prophylactic measures
  386. Isoniazid + rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet
    Indications
    Tuberculosis
  387. Isoniazid + rifapentine Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 300 mg + 300 mg tablet (scored)
    Indications
    Latent tuberculosis
  388. Isoprenaline Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 20 µg per mL in ampoule (hydrochloride)
    • Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)
    Indications
    Bradycardia Cardiogenic shock
  389. Isosorbide dinitrate Informations générales
    Section
    Antianginal medicines
    • Oral > Solid: 5 mg sublingual tablet
    Indications
    Angina pectoris
  391. Ivermectin Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 3 mg
    Indications
    Strongyloidiasis Ascariasis Trichuriasis Hookworm diseases Ancylostomiasis
    Section
    Antifilarials
    • Oral > Solid > tablet: 3 mg
    Indications
    Onchocerciasis Lymphatic filariasis
    Section
    Medicines for ectoparasitic infections
    • Oral > Solid > tablet: 3 mg
    Indications
    Scabies
  392. Kanamycin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis
  393. Kanamycin (injection) Informations générales
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1000 mg powder for injection (vial)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  394. Ketamine Informations générales
    Section
    General anaesthetics and oxygen > Injectable medicines
    • Parenteral > General injections > unspecified: 50 mg per mL in 10 mL vial (as hydrochloride)
    Indications
    Anaesthetics and therapeutic gases
  395. Ketoconazole Informations générales
    Section
    Medicines for endocrine disorders
    • Oral > Solid > tablet: 200 mg
    Indications
    Cushing syndrome
  396. Lactulose Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid
    Indications
    Palliative care
  397. Lamivudine Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 150 mg tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  398. Lamivudine + nevirapine + zidovudine Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  400. Lamivudine + zidovudine Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  401. Lamotrigine Informations générales
    Section
    Antiseizure medicines
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)
    Indications
    Epilepsy or seizures
  402. Latanoprost Informations générales
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops
    Indications
    Primary open-angle glaucoma
  403. Ledipasvir + sofosbuvir Informations générales
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 90 mg + 400 mg tablet
    Indications
    Chronic hepatitis C
  404. Lenalidomide Informations générales
    Section
    Immunomodulators
    • Oral > Solid: 25 mg
    Indications
    Plasma cell myeloma
  405. Letrozole Informations générales
    Section
    Ovulation inducers
    • Oral > Solid > dosage form: 2.5 mg
    Indications
    Female infertility without specification whether primary or secondary
  406. Leuprorelin Informations générales
    Section
    Hormones and antihormones
    • Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
    Indications
    Malignant neoplasms of breast Malignant neoplasms of prostate
  407. Levamisole Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)
    Indications
    Ascariasis
  408. Levetiracetam Informations générales
    Section
    Antiseizure medicines
    • Oral > Liquid: 100 mg per mL
    • Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg
    • Parenteral > General injections > IV: 500 mg per 5 mL in 5 mL vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag
    Indications
    Epilepsy or seizures Status epilepticus
  409. Levodopa Informations générales
    Section
    Antiseizure medicines
    • Oral > Solid: 250 mg
    Indications
    Parkinson disease
  410. Levodopa + benserazide Informations générales
    Section
    Medicines for parkinsonism
    Indications
    Therapeutic equivalent to levodopa + carbidopa pour Parkinson disease
  411. Levodopa + carbidopa Informations générales
    Section
    Medicines for parkinsonism
    • Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet
    Indications
    Parkinson disease
  412. Levofloxacin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  413. Levonorgestrel Informations générales
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 750 µg [2]; 1.5 mg [1]
    • Oral > Solid: 30 µg
    Indications
    Contact with health services for postcoital contraception Contact with health services for contraceptive management
    Section
    Intrauterine devices
    • Intrauterine system with reservoir containing 52 mg of levonorgestrel.
    Indications
    Contact with health services for insertion of contraceptive device
  414. Levonorgestrel-releasing implant Informations générales
    Section
    Implantable contraceptives
    • Implant > Subdermal: 75 mg per rod (two-rods)
    Indications
    Contact with health services for insertion of contraceptive device
  415. Levothyroxine Informations générales
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)
    Indications
    Hypothyroidism
  416. Lidocaine Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)
    Indications
    Ventricular tachyarrhythmia
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
    • Parenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride)
    • Local > Topical > unspecified: 2 to 4% (hydrochloride)
    Indications
    Local anaesthetics
  417. Lidocaine + epinephrine Informations générales
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial
    • Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine
    Indications
    Local anaesthetics
  418. Lindane Informations générales
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Cream: 1%
    • Local > Topical > Lotion: 1%
    Indications
    Scabies
  419. Linezolid Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 400 mg tablet; 600 mg tablet
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 600 mg
    Indications
    Other specified bacterial diseases Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus
    Section
    Antituberculosis medicines
    • Oral > Solid: 600 mg tablet; 150 mg tablet (dispersible)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  420. Liraglutide Informations générales
    Section
    Medicines for endocrine disorders
    • Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen
    Indications
    Obesity
  421. Lisinopril + amlodipine Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg
    Indications
    Essential hypertension
  422. Lisinopril + hydrochlorothiazide Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg
    Indications
    Essential hypertension
  423. Lisocabtagene maraleucel Informations générales
    Section
    Antineoplastics and supportive medicines
    Indications
    Therapeutic equivalent to axicabtagene ciloleucel pour Diffuse large B-cell lymphomas
  424. Lithium carbonate Informations générales
    Section
    Medicines for bipolar disorders
    • Oral > Solid: 300 mg
    Indications
    Bipolar or related disorders
  425. Long-acting insulin analogues Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    Indications
    Type 1 diabetes mellitus Type 2 diabetes mellitus
  426. Loperamide Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 2 mg solid oral dosage form
    Indications
    Palliative care
  427. Lopinavir + ritonavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  428. Loratadine Informations générales
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 1 mg per mL
    • Oral > Solid: 10 mg
    Indications
    Allergic or hypersensitivity conditions of unspecified type
  429. Lorazepam Informations générales
    Section
    Antiseizure medicines
    • Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule
    Indications
    Status epilepticus
    Section
    Medicines for anxiety disorders
    Indications
    Therapeutic equivalent to diazepam pour Anxiety
  430. Losartan Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Indications
    Essential hypertension
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Indications
    Heart failure
  431. Lovastatin Informations générales
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis
  432. Lugol's solution Informations générales
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)
    Indications
    Thyrotoxicosis
  433. Magnesium sulfate Informations générales
    Section
    Antiseizure medicines
    • Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
    • Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)
    Indications
    Severe pre-eclampsia Eclampsia
  434. Mannitol Informations générales
    Section
    Diuretics
    • Parenteral > General injections > IV: 10% solution; 20% solution
    Indications
    Ocular hypertension Cerebral oedema
  435. Measles vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against measles alone
  436. Mebendazole Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)
    Indications
    Ascariasis Enterobiasis Trichuriasis Hookworm diseases
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 500 mg (chewable); 100 mg (chewable)
    Indications
    Other specified echinococcosis
  437. Medroxyprogesterone acetate Informations générales
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
    • Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system
    Indications
    Contact with health services for reasons associated with reproduction
    Section
    Progestogens
    • Oral > Solid: 5 mg
    Indications
    Excessive menstruation with irregular cycle
  438. Mefloquine Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 250 mg tablet (hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 250 mg tablet (hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum
  439. Meglumine antimoniate Informations générales
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule
    Indications
    Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis
  440. Meglumine iotroxate Informations générales
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL
    Indications
    X-ray contrast media, iodinated
  441. Melarsoprol Informations générales
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)
    Indications
    African trypanosomiasis
  442. Melphalan Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    • Oral > Solid: 2 mg
    Indications
    Plasma cell myeloma
  443. Meningococcal meningitis vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  445. Meropenem Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Second choix
    Neutropenia (high-risk) Peritoneal abscess (severe) Peritonitis (severe) Neonatal meningitis
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  446. Meropenem + vaborbactam Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii
  447. Mesalazine Informations générales
    Section
    Anti-inflammatory medicines
    Indications
    Therapeutic equivalent to sulfasalazine pour Crohn disease site Therapeutic equivalent to sulfasalazine pour Ulcerative colitis
  449. Metformin Informations générales
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 500 mg (hydrochloride)
    Indications
    Type 2 diabetes mellitus
  450. Methadone Informations générales
    Section
    Medicines for opioid use disorders
    • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
    Indications
    Opioid dependence
    Section
    Opioid analgesics
    • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
    • Oral > Solid: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)
    Indications
    Chronic cancer pain
  451. Methimazole Informations générales
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 5 mg; 10 mg; 20 mg
    Indications
    Thyrotoxicosis
  452. Methionine Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 250 mg (DL)
    Indications
    Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs
  453. Methotrexate Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
    • Oral > Solid: 2.5 mg (as sodium salt)
    • Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Malignant trophoblastic neoplasms of placenta Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)
    Indications
    Psoriasis of unspecified type
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid > tablet: 2.5 mg (as sodium salt)
    Indications
    Rheumatoid arthritis, serology unspecified
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: pre-filled syringe in multiple strengths
    Indications
    Crohn disease site Psoriatic arthritis
    Section
    Medicines for juvenile joint diseases
    • Oral > Solid > tablet: 2.5 mg (as sodium salt)
    Indications
    Juvenile idiopathic arthritis
  454. Methoxy polyethylene glycol-epoetin beta Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  455. Methyldopa Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 250 mg
    Indications
    Essential hypertension Gestational hypertension
  456. Methylergometrine Informations générales
    Section
    Uterotonics
    Indications
    Therapeutic equivalent to ergometrine pour Postpartum haemorrhage
  457. Methylphenidate Informations générales
    Section
    Medicines for mental and behavioural disorders
    • Multiple formulations and strengths.
    Indications
    Attention deficit hyperactivity disorder
  458. Methylprednisolone Informations générales
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)
    Indications
    Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia
  459. Methylthioninium chloride Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule
    Indications
    Acquired methaemoglobinaemia
  460. Metoclopramide Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Palliative care
    Section
    Antiemetic medicines
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Nausea or vomiting
  461. Metoprolol Informations générales
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Angina pectoris
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol pour Heart failure
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Essential hypertension
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Cardiac arrhythmia
  462. Metronidazole Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Oral > Solid: 200 to 500 mg tablet
    • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
    • Local > Rectal > Suppository: 500 mg suppository; 1 g suppository
    Indications
    Premier choix
    co-prescrite avec cefazolin Other specified prophylactic measures co-prescrite avec cefotaxime Peritoneal abscess (severe) co-prescrite avec cefotaxime Peritonitis (severe) co-prescrite avec cefotaxime Peritonitis (mild-moderate) co-prescrite avec cefotaxime Peritoneal abscess (mild-moderate) co-prescrite avec ceftriaxone Peritoneal abscess (severe) co-prescrite avec ceftriaxone Peritoneal abscess (mild-moderate) co-prescrite avec ceftriaxone Peritonitis (severe) co-prescrite avec ceftriaxone Peritonitis (mild-moderate)
    Second choix
    co-prescrite avec ciprofloxacin Peritoneal abscess (mild-moderate) co-prescrite avec ciprofloxacin Peritonitis (mild-moderate)
    Autres indications
    Bacterial infection of unspecified site
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Parenteral > General injections > unspecified: 500 mg in 100 mL vial
    • Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
    Indications
    Amoebiasis
  463. Micafungin Informations générales
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection
    Indications
    Systemic or invasive candidosis
  464. Miconazole Informations générales
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Cream: 2% (nitrate)
    • Local > Topical > Ointment: 2% (nitrate)
    Indications
    Fungal infection of the skin
  465. Midazolam Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL oral liquid
    • Oral > Solid: 7.5 mg solid oral dosage form; 15 mg solid oral dosage form
    • Parenteral > General injections > unspecified: 1 mg per mL injection; 5 mg per mL injection
    Indications
    Palliative care
    Section
    Antiseizure medicines
    • Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration)
    • Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)
    Indications
    Therapeutic equivalent to lorazepam pour Status epilepticus Status epilepticus
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 1 mg per mL
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 15 mg tablet; 7.5 mg tablet
    Indications
    Sedative-hypnotic and anxiolytic drugs
  466. Mifepristone - misoprostol Informations générales
    Section
    Uterotonics
    • Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package
    Indications
    Induced abortion Unspecified time of fetal death, cause not specified
  467. Miltefosine Informations générales
    Section
    Antileishmaniasis medicines
    • Oral > Solid: 10 mg; 50 mg
    Indications
    Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis
  468. Misoprostol Informations générales
    Section
    Uterotonics
    • Oral > Solid: 200 µg
    • Local > Vaginal > tablet: 25 µg
    Indications
    Spontaneous abortion, incomplete, without complication Unspecified obstetric condition Postpartum haemorrhage
  469. Mometasone Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide pour Asthma
  470. Mometasone + formoterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol pour Asthma
  471. Morphine Informations générales
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 10 mg in 1 mL ampoule (sulfate OR hydrochloride)
    Indications
    Opioids or related analgesics and agents affecting opioid receptors
    Section
    Opioid analgesics
    • Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)
    • Oral > Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate)
    • Oral > Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate)
    • Parenteral > General injections > unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
    Indications
    Pain
  472. Moxifloxacin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible)
    • Oral > Solid: 400 mg tablet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis Tuberculosis
  473. Multiple micronutrient powder Informations générales
    Section
    Vitamins and minerals
    • Oral > Other:
    Indications
    Iron deficiency anaemia
  474. Multiple micronutrient supplement Informations générales
    Section
    Other medicines administered to the mother
    • Tablet containing:
    • Vit A: 800 mcg retinol activity equivalent
    • Vit C: 70 mg
    • Vit D: 5 mcg (200 IU)
    • Vit E: 10 mg alpha tocopherol equivalent
    • Vit B1: 1.4 mg
    • Vit B2: 1.4 mg
    • Vit B3: 18 mg niacin equivalent
    • Vit B6: 1.9 mg
    • Folic acid: 400 mcg
    • Vit B12: 2.6 mcg
    • Iron: 30 mg
    • Iodine: 150 mcg
    • Zinc: 15 mg
    • Selenium: 65 mcg
    • Copper: 2 mg
    Indications
    Maternal care for other specified conditions predominantly related to pregnancy
  475. Mumps vaccine Informations générales
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against mumps alone
  476. Mupirocin Informations générales
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Cream: 2% (as mupirocin calcium)
    • Local > Topical > Ointment: 2%
    Indications
    Superficial bacterial folliculitis Impetigo
  477. Nadroparin Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin pour Acute ischaemic heart disease Therapeutic equivalent to enoxaparin pour Venous thromboembolism
  478. Nalidixic acid Informations générales
    Section
    Anti-infective medicines
    • Oral > Solid: 250 mg; 500 mg
    Indications
    Shigella resistant to unspecified antibiotic
  479. Naloxone Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)
    Indications
    Unintentional exposure to or harmful effects of opioids or related analgesics
  480. Naltrexone Informations générales
    Section
    Medicines for alcohol use disorders
    • Parenteral > General injections > IM: 380 mg in vial (extended-release)
    • Oral > Solid > tablet: 50 mg
    Indications
    Disorders due to use of alcohol
  481. Natamycin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Suspension: 5% eye drops
    Indications
    Infectious keratitis
  482. Nelfinavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 250 mg (as mesilate)
    • Oral > Other: 50 mg per g oral powder
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  483. Neostigmine Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Oral > Solid: 15 mg (neostigmine bromide)
    • Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
    Indications
    Myasthenia gravis Anticholinesterase reversible
  484. Netilmicin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis
  485. Nevirapine Informations générales
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL oral solution
    • Oral > Solid: 200 mg tablet; 50 mg tablet (dispersible)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  486. Niclosamide Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid: 500 mg tablet (chewable)
    Indications
    Hymenolepiasis Diphyllobothriasis Taeniasis due to Taenia saginata Taeniasis due to Taenia solium
  487. Nicotinamide Informations générales
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
    Pellagra
  488. Nicotine replacement therapy Informations générales
    Section
    Medicines for nicotine use disorders
    • Oral > Other: 2 mg chewing gum; 4 mg chewing gum; 2 mg lozenge; 4 mg lozenge; 1 mg per actuation oral spray
    • Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour
    Indications
    Nicotine dependence
  489. Nifedipine Informations générales
    Section
    Antioxytocics (tocolytics)
    • Oral > Solid: 10 mg (immediate-release)
    Indications
    Preterm labour without delivery
    Section
    Antianginal medicines
    • Oral > Solid: 10 mg
    Indications
    Angina pectoris
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg tablet; sustained-release formulations
    Indications
    Essential hypertension
  490. Nifurtimox Informations générales
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid > tablet: 120 mg (scored); 30 mg (scored)
    Indications
    African trypanosomiasis
    Section
    American trypanosomiasis
    • Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)
    Indications
    Chagas disease
  491. Nilotinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 150 mg capsule; 200 mg capsule
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  492. Nilutamide Informations générales
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide pour Malignant neoplasms of prostate
  493. Nitrofurantoin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL oral liquid
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    Premier choix
    Infectious cystitis
  494. Nitrous oxide Informations générales
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation:
    Indications
    Anaesthetics and therapeutic gases
  495. Nivolumab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
    Indications
    Other specified malignant neoplasms of bronchus or lung Melanoma of skin
  496. Norethisterone Informations générales
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 350 µg
    Indications
    Contact with health services for contraceptive management
    Section
    Progestogens
    • Oral > Solid: 5 mg
    Indications
    Excessive menstruation with irregular cycle Therapeutic equivalent to medroxyprogesterone acetate pour Excessive menstruation with irregular cycle
  497. Norethisterone enantate Informations générales
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution
    Indications
    Contact with health services for reasons associated with reproduction
  498. Normal immunoglobulin Informations générales
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
    • Parenteral > General injections > IM: 16% protein solution
    • Parenteral > General injections > SC: 15% protein solution; 16% protein solution
    Indications
    Primary immunodeficiencies Mucocutaneous lymph node syndrome Langerhans cell histiocytosis
  499. Nystatin Informations générales
    Section
    Antifungal medicines
    • Oral > Liquid: 100000 IU per mL
    • Local > Topical > Other: 100000 IU pessary
    • Oral > Solid > dosage form: 500000 IU
    • Oral > Solid > lozenge: 100000 IU
    Indications
    Candidosis
  500. Ocrelizumab Informations générales
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > IV: 30 mg per mL in 10 vial concentrate for solution
    • Parenteral > General injections > IV: 30 mg per mL in 10 mL vial
    Indications
    Multiple sclerosis Relapsing-remitting multiple sclerosis
  501. Octreotide Informations générales
    Section
    Medicines for disorders of the pituitary hormone system
    • Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent
    • Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)
    Indications
    Acromegaly or pituitary gigantism
  502. Ofloxacin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 200 mg; 400 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
    Section
    Ear, nose and throat medicines [c]
    Indications
    Therapeutic equivalent to ciprofloxacin pour Infectious diseases of external ear
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.3%
    Indications
    Other specified conjunctivitis Infectious keratitis
  503. Olanzapine Informations générales
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 10 mg in vial powder for injection
    Indications
    Therapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders
  504. Omadacycline Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 100 mg lyophilized powder for injection
    • Oral > Solid: 300 mg
    Indications
    Methicillin resistant Staphylococcus aureus
  505. Ombitasvir + paritaprevir + ritonavir Informations générales
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet
    Indications
    Chronic hepatitis C
  506. Omeprazole Informations générales
    Section
    Antiulcer medicines
    • Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid
    • Oral > Solid: 10 mg; 20 mg; 40 mg
    • Parenteral > General injections > IV: 40 mg in vial
    Indications
    Peptic ulcer, site unspecified Gastro-oesophageal reflux disease Gastrointestinal bleeding
  507. Ondansetron Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
    • Oral > Liquid: 4 mg per 5 mL (ondansetron base)
    • Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base)
    Indications
    Palliative care
    Section
    Antiemetic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
    • Oral > Liquid: 4 mg per 5 mL (ondansetron base)
    • Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base); 24 mg (ondansetron base)
    Indications
    Nausea or vomiting
  508. Oral rehydration salts Informations générales
    Section
    Oral rehydration
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
    Indications
    Diarrhoea
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Oral
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
  509. Oral rehydration salts - zinc sulfate Informations générales
    Section
    Medicines used in diarrhoea
    • Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)
    Indications
    Diarrhoea
  510. Oseltamivir Informations générales
    Section
    Other antivirals
    • Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)
    Indications
    Influenza due to identified seasonal influenza virus
  511. Osimertinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)
    Indications
    Other specified malignant neoplasms of bronchus or lung
  512. Oxaliplatin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon
  513. Oxamniquine Informations générales
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid: 250 mg capsule
    Indications
    Schistosomiasis due to Schistosoma mansoni
  514. Oxazolindinones Informations générales
    Section
    Reserve group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  515. Oxycodone Informations générales
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine pour Pain
  516. Oxygen Informations générales
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation: (medical gas)
    Indications
    Anaesthetics and therapeutic gases
    Section
    Medical gases
    • Respiratory > Inhalation:
    Indications
    Respiratory failure as acute or chronic
  517. Oxytetracycline Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to tetracycline pour Other specified conjunctivitis Therapeutic equivalent to tetracycline pour Infectious keratitis Therapeutic equivalent to tetracycline pour Infectious blepharitis Therapeutic equivalent to tetracycline pour Trachoma
  518. Oxytocin Informations générales
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 10 IU per mL
    Indications
    Postpartum haemorrhage
  519. P-aminosalicylate sodium Informations générales
    Section
    Antituberculosis medicines
    • Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  520. P-aminosalicylic acid Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 4 g granules in sachet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  522. Palbociclib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 75 mg; 100 mg; 125 mg
    Indications
    Other specified malignant neoplasms of breast
  523. Paliperidone Informations générales
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)
    Indications
    Therapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders
  524. Palonosetron Informations générales
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron pour Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron pour Nausea or vomiting
  525. Pancreatic enzymes Informations générales
    Section
    Pancreatic enzymes
    • Oral > Solid: Age-appropriate formulations and doses including lipase, protease and amylase.
    Indications
    Enzyme intestinal
  526. Paracetamol (acetaminophen) Informations générales
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
    • Local > Rectal > Suppository: 100 mg; 250 mg
    • Oral > Solid > dispersible tablet: 100 mg; 250 mg
    • Oral > Solid > tablet: 250 mg; 325 mg; 500 mg
    Indications
    Pain
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
    • Local > Rectal > Suppository: 250 mg
    • Oral > Solid > dispersible tablet: 100 mg; 250 mg
    • Oral > Solid > tablet: 250 mg; 325 mg; 500 mg
    Indications
    Migraine
  527. Paromomycin Informations générales
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)
    Indications
    Visceral leishmaniasis
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Liquid: 125 mg per 5 mL as sulfate
    • Oral > Solid: 250 mg as sulfate
    Indications
    Amoebiasis
  528. Pegaspargase Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  529. Pegfilgrastim Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe
    Indications
    Acquired neutropaenia
  530. Pegylated interferon alfa (2a) Informations générales
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe
    Indications
    Chronic hepatitis C
  531. Pegylated interferon alfa (2b) Informations générales
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe
    Indications
    Chronic hepatitis C
  532. Pembrolizumab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 50 mg powder for injection
    Indications
    Therapeutic equivalent to nivolumab pour Melanoma of skin Other specified malignant neoplasms of bronchus or lung
  533. Penicillamine Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 250 mg
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 250 mg
    Indications
    Rheumatoid arthritis, serology unspecified
  534. Pentamidine Informations générales
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)
    Indications
    Visceral leishmaniasis
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 200 mg tablet; 300 mg tablet
    Indications
    Pneumocystosis
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection
    Indications
    African trypanosomiasis
  535. Permethrin Informations générales
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Lotion: 1%
    • Local > Topical > Cream: 5%
    Indications
    Pediculosis corporis Pediculosis capitis Scabies
  536. Pertussis vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against pertussis alone
  537. Pertuzumab Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution
    Indications
    Carcinoma of breast, specialised type
  538. Phenelzine Informations générales
    Section
    Medicines for depressive disorders
    • Oral > Solid > dosage form: 15 mg (as sulfate)
    Indications
    Other specified depressive disorders
  539. Phenobarbital Informations générales
    Section
    Antiseizure medicines
    • Oral > Liquid: 15 mg per 5 mL
    • Oral > Solid: 15 to 100 mg
    • Parenteral > General injections > IV: 200 mg per mL (phenobarbital sodium); 30 mg per mL (phenobarbital sodium); 60 mg per mL (phenobarbital sodium)
    Indications
    Epilepsy or seizures Status epilepticus
  540. Phenoxymethylpenicillin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 250 mg (as potassium salt) tablet
    • Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)
    Indications
    Premier choix
    Acute pharyngitis Periapical abscess without sinus Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
    Autres indications
    Bacterial infection of unspecified site
  541. Phenytoin Informations générales
    Section
    Antiseizure medicines
    • Oral > Liquid: 30 mg per 5 mL (phenytoin)
    • Parenteral > General injections > unspecified: 50 mg per mL in vial (phenytoin sodium)
    • Oral > Solid > tablet: 50 mg (phenytoin) (chewable)
    • Oral > Solid > dosage form: 50 mg (phenytoin sodium); 25 mg (phenytoin sodium); 100 mg (phenytoin sodium)
    Indications
    Epilepsy or seizures
  542. Phosphorus Informations générales
    Section
    Medicines for endocrine disorders
    • Oral > Other: 500 mg in sachet (elemental phosphorus) granules
    • Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent)
    Indications
    Hypophosphataemic rickets
  543. Phytomenadione Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule
    • Oral > Solid: 10 mg tablet
    Indications
    Haemorrhagic disorder due to other specified circulating anticoagulants Haemorrhagic or haematological disorders of fetus or newborn
  544. Pilocarpine Informations générales
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)
    Indications
    Acute angle closure with pupillary block Ocular hypertension Primary open-angle glaucoma
  545. Piperacillin + tazobactam Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
    Indications
    Premier choix
    Peritoneal abscess (severe) Other specified pneumonia (Hospital-acquired pneumonia) Neutropenia (high-risk) Peritonitis (severe) co-prescrite avec clindamycin Necrotising fasciitis
  546. Platelets Informations générales
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  547. Plazomicin Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500 mg per 10 mL (Injection)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  548. Pneumococcal vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  549. Podophyllotoxin Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to podophyllum resin pour Anogenital warts Therapeutic equivalent to podophyllum resin pour Plantar warts
  550. Podophyllum resin Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 10 to 25%
    Indications
    Anogenital warts Plantar warts
  551. Poliomyelitis vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against poliomyelitis
  552. Polygeline Informations générales
    Section
    Plasma substitutes
    • Parenteral > General injections > IV: 3.5% injectable solution
    • Parenteral > General injections > IV: 3.5% in solution
    Indications
    Therapeutic equivalent to dextran 70 pour Hypovolaemia Hypovolaemia
  553. Polymyxin B (injection) Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  554. Polymyxins Informations générales
    Section
    Reserve group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  555. Potassium chloride Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Oral
    • Oral > Liquid: powder for solution
    Indications
    Hypokalaemia
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)
    Indications
    Hypokalaemia
  556. Potassium ferric hexacyanoferrate Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: Powder for oral administration
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  557. Potassium iodide Informations générales
    Section
    Antifungal medicines
    • Local > Topical > Solution: Saturated solution
    Indications
    Sporotrichosis
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 60 mg
    Indications
    Thyrotoxicosis
  558. Potassium permanganate Informations générales
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Solution: aqueous solution: 1:10 000
    Indications
    Tropical phagedaenic ulcer Pemphigus Other specified pyogenic bacterial infection of skin and subcutaneous tissue Impetigo
  559. Povidone iodine Informations générales
    Section
    Antiseptics
    • Local > Topical > Solution: 10% (equivalent to 1% available iodine)
    Indications
    Povidone iodine
  560. Pralidoxime Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • .
    Indications
    Exposure to or harmful effects of undetermined intent of pesticides
  561. Pramipexole Informations générales
    Section
    Antiseizure medicines
    • Oral > Solid: 125 µg immediate-release; 250 mg immediate-release; 500 µg immediate-release; 750 µg immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 µg extended-release; 750 µg extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 extended-release
    Indications
    Parkinson disease
  562. Pravastatin Informations générales
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis
  563. Praziquantel Informations générales
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
    Indications
    Paragonimiasis Clonorchiasis Opisthorchiasis Schistosomiasis
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
    Indications
    Taeniasis due to Taenia saginata Taeniasis due to Taenia solium Diphyllobothriasis Hymenolepiasis
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
    Indications
    Cysticercosis of central nervous system
  564. Precipitated sulfur Informations générales
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Ointment:
    Indications
    Therapeutic equivalent to benzyl benzoate pour Pthiriasis Therapeutic equivalent to benzyl benzoate pour Pediculosis corporis Therapeutic equivalent to benzyl benzoate pour Pediculosis capitis Therapeutic equivalent to benzyl benzoate pour Scabies
  565. Prednisolone Informations générales
    Section
    Hormones and antihormones
    • Oral > Liquid: 5 mg per mL
    • Oral > Solid: 5 mg; 25 mg
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Plasma cell myeloma Follicular lymphoma Lymphoid leukaemia, not elsewhere classified Malignant neoplasms of prostate Chronic lymphocytic leukaemia or small lymphocytic lymphoma Hodgkin lymphoma Diffuse large B-cell lymphomas Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis
    Section
    Anti-inflammatory medicines
    • Local > Rectal > Retention enema:
    • Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)
    Indications
    Therapeutic equivalent to hydrocortisone pour Crohn disease site Crohn disease site Ulcerative colitis
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 5 mg per mL
    • Oral > Solid: 5 mg; 25 mg
    Indications
    Allergic or hypersensitivity conditions of unspecified type
    Section
    Ophthalmological preparations > Anti-inflammatory agents
    • Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)
    Indications
    Scleritis Anterior uveitis
  566. Prednisone Informations générales
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to prednisolone pour Plasma cell myeloma Therapeutic equivalent to prednisolone pour Follicular lymphoma Therapeutic equivalent to prednisolone pour Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone pour Malignant neoplasms of prostate Therapeutic equivalent to prednisolone pour Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone pour Hodgkin lymphoma Therapeutic equivalent to prednisolone pour Diffuse large B-cell lymphomas Therapeutic equivalent to prednisolone pour Anaplastic large cell lymphoma, ALK-negative Therapeutic equivalent to prednisolone pour Anaplastic large cell lymphoma, ALK-positive Therapeutic equivalent to prednisolone pour Langerhans cell histiocytosis
    Section
    Antiallergics and medicines used in anaphylaxis
    Indications
    Therapeutic equivalent to prednisolone pour Allergic or hypersensitivity conditions of unspecified type
  567. Pretomanid Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 200 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  568. Primaquine Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)
    Indications
    Malaria due to Plasmodium ovale Malaria due to Plasmodium vivax
  569. Probenecid Informations générales
    Section
    Medicines used to treat gout
    • Oral > Solid: 500 mg
    Indications
    Gout
  570. Procainamide Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule (hydrochloride)
    • Oral > Solid: 500 mg (hydrochloride); 250 mg (hydrochloride)
    Indications
    Cardiac arrhythmia
  571. Procaine benzylpenicillin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection
    Indications
    Premier choix
    Congenital syphilis [children]
    Second choix
    Syphilis
  572. Procarbazine Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 50 mg (as hydrochloride)
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Hodgkin lymphoma
  573. Progesterone vaginal ring Informations générales
    Section
    Intravaginal contraceptives
    • Local > Vaginal > vaginal ring: 2.074 g micronized progesterone
    Indications
    Contact with health services for contraceptive management
  574. Proguanil Informations générales
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 100 mg tablet (hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum
  575. Promethazine Informations générales
    Section
    Antiemetic medicines
    • Oral > Liquid: 5 mg per 5 mL (hydrochloride)
    • Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule
    Indications
    Nausea or vomiting
  576. Propanol Informations générales
    Section
    Antiseptics
    Indications
    Therapeutic equivalent to ethanol pour Denatured alcohol
  577. Propofol Informations générales
    Section
    General anaesthetics and oxygen > Injectable medicines
    • Parenteral > General injections > IV: 10 mg per mL; 20 mg per mL
    Indications
    Anaesthetics and therapeutic gases
  578. Propranolol Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 80 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)
    Indications
    Essential hypertension
    Section
    Antianginal medicines
    • Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)
    • Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)
    Indications
    Angina pectoris
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)
    • Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)
    Indications
    Cardiac arrhythmia
    Section
    Antimigraine medicines > For prophylaxis
    • Oral > Solid: 40 mg tablet (hydrochloride); 20 mg tablet (hydrochloride)
    Indications
    Migraine
  579. Propylthiouracil Informations générales
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 mg
    Indications
    Thyrotoxicosis
  580. Prostaglandin E1 Informations générales
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 0.5 mg per mL in alcohol
    Indications
    Other specified congenital anomaly of great arteries including arterial duct
  581. Prostaglandin E2 Informations générales
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 1 mg per mL
    Indications
    Therapeutic equivalent to prostaglandin E1 pour Other specified congenital anomaly of great arteries including arterial duct Other specified congenital anomaly of great arteries including arterial duct
  582. Protamine sulfate Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule
    Indications
    Haemorrhagic disorder due to other specified circulating anticoagulants
  583. Protionamide Informations générales
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to ethionamide pour Multi-drug resistant Mycobacterium tuberculosis
  584. Pyrantel Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)
    Indications
    Ascariasis Enterobiasis Trichuriasis Hookworm diseases
  585. Pyrazinamide Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 400 mg; 150 mg tablet (dispersible); 500 mg
    Indications
    Tuberculosis
  586. Pyridostigmine Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 1 mg in 1 mL ampoule (pyridostigmine bromide)
    • Oral > Solid: 60 mg (pyridostigmine bromide)
    Indications
    Myasthenia gravis
  587. Pyridoxine Informations générales
    Section
    Vitamins and minerals
    • Oral > Solid: 25 mg (hydrochloride)
    Indications
    Vitamin B6 deficiency Sideroblastic anaemia Other specified polyneuropathy
  588. Pyrimethamine Informations générales
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 25 mg
    Indications
    Toxoplasmosis
  589. Quetiapine Informations générales
    Section
    Medicines for psychotic disorders
    Indications
    Therapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders
    Section
    Medicines for bipolar disorders
    • Oral > Solid > tablet: 25 mg (immediate-release); 100 mg (immediate-release); 150 mg (immediate-release); 200 mg (immediate-release); 300 mg (immediate-release); 50 mg (modified-release); 150 mg (modified-release); 200 mg (modified-release); 300 mg (modified-release); 400 mg (modified-release)
    Indications
    Bipolar or related disorders
  590. Quinidine Informations générales
    Section
    Antiarrhythmic medicines
    • Oral > Solid: 200 mg (sulfate)
    Indications
    Cardiac arrhythmia
  591. Quinine Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride)
    • Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)
    Indications
    Malaria due to Plasmodium falciparum
  592. Rabies vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rabies
  593. Raltegravir Informations générales
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Liquid: 100 mg granules for oral suspension
    • Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  594. Ranibizumab Informations générales
    Section
    Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
    • .
    Indications
    Retinal venous occlusions Diabetic macular oedema Degenerative high myopia Age related macular degeneration
  595. Ranitidine Informations générales
    Section
    Antiulcer medicines
    • Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride)
    • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)
    Indications
    Gastro-oesophageal reflux disease Peptic ulcer, site unspecified
  596. Rasburicase Informations générales
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution
    Indications
    Tumour lysis syndrome
  597. Ravidasvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 200 mg
    Indications
    Chronic hepatitis C
  598. Ready to use therapeutic food Informations générales
    Section
    Therapeutic foods
    • Biscuit or paste of nutritional composition as determined by the UN joint statement on the community-based management of severe acute malnutrition and Codex alimentarius guidelines.
    Indications
    Acute malnutrition in infants, children or adolescents
  599. Realgar-indigo naturalis formulation Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  600. Red blood cells Informations générales
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  601. Resin-based composite (high-viscosity) Informations générales
    Section
    Dental medicines and preparations
    • Local > Topical > Other: Single-use capsule or multi-use syringe
    Indications
    Dental caries
  602. Resin-based composite (low-viscosity) Informations générales
    Section
    Dental medicines and preparations
    • Local > Topical > Other: Single-use applicator or multi-use bottle
    Indications
    Dental caries
  603. Retinol Informations générales
    Section
    Vitamins and minerals
    • Parenteral > General injections > IM: 100000 IU in 2 mL ampoule (as palmitate) water-miscible injection
    • Oral > Liquid: 100000 IU per mL (as palmitate) oral oily solution in multidose dispenser
    • Oral > Solid: 10000 IU (as palmitate) sugar-coated tablet; 200000 IU (as palmitate) capsule; 50000 IU (as palmitate) capsule; 100000 IU (as palmitate) capsule
    Indications
    Vitamin A deficiency
  604. Ribavirin Informations générales
    Section
    Other antivirals
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Indications
    Viral haemorrhagic fever, not elsewhere classified
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Indications
    Chronic hepatitis C
  605. Ribociclib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to palbociclib pour Other specified malignant neoplasms of breast
  606. Riboflavin Informations générales
    Section
    Vitamins and minerals
    • Oral > Solid: 5 mg
    Indications
    Vitamin B2 deficiency
  607. Rifabutin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg
    Indications
    Tuberculosis
  608. Rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    • Parenteral > General injections > IV: 600 mg in vial powder for injection
    Indications
    Tuberculosis Other specified tuberculosis
    Section
    Antileprosy medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Leprosy
  609. Rifapentine Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg tablet; 300 mg tablet
    Indications
    Tuberculosis Latent tuberculosis
  610. Risdiplam Informations générales
    Section
    Medicines for diseases of the nervous system
    • Oral > Liquid: 0.75 mg per mL powder for oral liquid
    Indications
    Spinal muscular atrophy
  611. Risperidone Informations générales
    Section
    Medicines for psychotic disorders
    • Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg
    • Parenteral > General injections > IM:
    Indications
    Schizophrenia or other primary psychotic disorders Therapeutic equivalent to paliperidone pour Schizophrenia or other primary psychotic disorders
  612. Ritonavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  613. Rituximab Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
    Indications
    Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas Burkitt lymphoma including Burkitt leukaemia
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial
    Indications
    Multiple sclerosis
  614. Rivaroxaban Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran pour Venous thromboembolism Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation
  615. Ropinirole Informations générales
    Section
    Antiseizure medicines
    • Oral > Solid: 0.25 mg immediate-release; 0.5 mg immediate-release; 1 mg immediate-release; 2 immediate-release; 3 mg immediate-release; 4 mg immediate-release; 5 mg immediate-release; 2 mg extended-release; 4 mg extended-release; 6 mg extended-release; 8 mg extended-release; 12 mg extended-release
    Indications
    Parkinson disease
  616. Rotavirus vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  617. Rubella vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rubella alone
  618. Salbutamol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Parenteral > General injections > IV: 50 µg per mL in 5 mL ampoule (as sulfate)
    • Respiratory > Inhalation > aerosol: 100 µg per dose (as sulfate); 100 µg per dose (as sulfate) metered-dose inhaler
    • Respiratory > Inhalation > solution: 5 mg per mL (as sulfate) for use in nebulizers
    Indications
    Chronic obstructive pulmonary disease Asthma
  619. Salicylic acid Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 5%
    Indications
    Seborrhoeic dermatitis Psoriasis of unspecified type Ichthyoses
  620. Saquinavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 200 mg; 500 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  621. Selenium sulfide Informations générales
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Suspension: 2% detergent-based
    Indications
    Seborrhoeic dermatitis Pityriasis versicolor
  622. Senna Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 7.5 mg per 5 mL oral liquid
    Indications
    Palliative care
    Section
    Laxatives
    • Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)
    Indications
    Constipation
  623. Sevoflurane Informations générales
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > liquid:
    Indications
    Anaesthetics and therapeutic gases
  624. Silver diamine fluoride Informations générales
    Section
    Dental medicines and preparations
    • Local > Dental > Solution: 38% w/v
    Indications
    Dental caries
  625. Silver nitrate Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 1%
    Indications
    Neonatal conjunctivitis or dacryocystitis
  626. Silver sulfadiazine Informations générales
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Cream: 1%
    Indications
    Burns
  627. Simeprevir Informations générales
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 150 mg
    Indications
    Chronic hepatitis C
  628. Simvastatin Informations générales
    Section
    Lipid-lowering agents
    • Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg
    Indications
    Mixed hyperlipidaemia Coronary atherosclerosis
    Section
    Medicines for endocrine disorders
    • Oral > Solid: 20 mg
    Indications
    Polycystic ovary syndrome
  629. Smallpox vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  630. Snake antivenom Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • .
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  631. Sodium calcium edetate Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  632. Sodium chloride Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L)
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
  633. Sodium hyaluronate Informations générales
    Section
    Ophthalmological preparations
    Indications
    Therapeutic equivalent to hypromellose pour Keratoconjunctivitis sicca
  634. Sodium hydrogen carbonate Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L)
    Indications
    Acidosis
  635. Sodium nitrite Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  636. Sodium nitroprusside Informations générales
    Section
    Antihypertensive medicines
    • Parenteral > General injections > IV: 50 mg in ampoule powder for infusion
    Indications
    Hypertensive crisis
  637. Sodium stibogluconate Informations générales
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial
    Indications
    Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis
  638. Sodium thiosulfate Informations générales
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Solution: 15%
    Indications
    Pityriasis versicolor
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  639. Sofosbuvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 400 mg; 200 mg
    Indications
    Chronic hepatitis C
  640. Sofosbuvir + velpatasvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 400 mg + 100 mg tablet; 200 mg + 50 mg tablet
    Indications
    Chronic hepatitis C
  641. Somatropin Informations générales
    Section
    Medicines for endocrine disorders
    • Parenteral > General injections > SC: 5 mg in cartridge powder for injection; 5 mg per mL in 2 mL cartridge
    Indications
    Hypoglycaemia without associated diabetes
  642. Spectinomycin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection
    Indications
    Second choix
    Gonococcal infection
    Autres indications
    Bacterial infection of unspecified site
  643. Spironolactone Informations générales
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg
    Indications
    Heart failure
    Section
    Diuretics
    • Oral > Liquid: 10 mg per 5 mL; 25 mg per 5 mL; 5 mg per 5 mL
    • Oral > Solid: 25 mg
    Indications
    Oedema Ascites
  644. Stavudine Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 5 mg per 5 mL powder for oral solution
    • Oral > Solid: 15 mg; 20 mg; 30 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  645. Streptokinase Informations générales
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 1.5 million IU in vial powder for injection
    Indications
    Acute myocardial infarction
  646. Streptomycin (injection) Informations générales
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  647. Succimer Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 100 mg
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  648. Sulfacetamide Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 10% (sodium salt)
    Indications
    Other specified conjunctivitis
  649. Sulfadiazine Informations générales
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 500 mg
    Indications
    Toxoplasmosis
    Section
    Anti-infective medicines
    • Oral > Solid: 500 mg
    • Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)
    Indications
    Bacterial infection of unspecified site
  650. Sulfadimidine Informations générales
    Section
    Anti-infective medicines
    • Oral > Liquid: 500 mg per 5 mL
    • Oral > Solid: 500 mg
    • Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)
    Indications
    Bacterial infection of unspecified site
  651. Sulfadoxine + pyrimethamine Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 500 mg + 25 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 500 mg + 25 mg tablet
    • Oral > Solid: 250 mg + 12.5 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria
  652. Sulfamethoxazole + trimethoprim Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    • Oral > Solid > dispersible tablet: 100 mg + 20 mg
    Indications
    Premier choix
    Infectious cystitis
    Second choix
    Infectious gastroenteritis or colitis without specification of infectious agent
    Autres indications
    Bacterial infection of unspecified site
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    • Oral > Solid > dispersible tablet: 100 mg + 20 mg
    Indications
    Pneumocystosis
  653. Sulfasalazine Informations générales
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 500 mg
    Indications
    Rheumatoid arthritis, serology unspecified
    Section
    Anti-inflammatory medicines
    • Oral > Solid: 500 mg
    • Local > Rectal > Suppository: 500 mg
    • Local > Rectal > Retention enema:
    Indications
    Crohn disease site Ulcerative colitis
  654. Sumatriptan Informations générales
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Solid: 50 mg
    Indications
    Migraine
  655. Sunscreen (broad-spectrum) Informations générales
    Section
    Dermatological medicines
    • Topical cream, lotion, gel, ointment, spray with sun protection factor ≥ 50.
    Indications
    Albinism or other specified genetically-determined hypomelanotic disorders Xeroderma pigmentosum
  656. Suramin sodium Informations générales
    Section
    Antifilarials
    • Parenteral > General injections > IV: 1 g in vial
    Indications
    Filariasis
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Parenteral > General injections > IV: 1 g in vial
    Indications
    African trypanosomiasis
  657. Surfactant Informations générales
    Section
    Medicines administered to the neonate [c]
    • Respiratory > Suspension: 80 mg per mL for intratracheal instillation; 25 mg per mL for intratracheal instillation
    Indications
    Respiratory distress syndrome of newborn
  658. Suxamethonium Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (suxamethonium chloride); powder for injection (suxamethonium chloride) in vial
    Indications
    Muscle relaxants
  659. Tacalcitol Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to calcipotriol pour Psoriasis of unspecified type
  660. Tacrolimus Informations générales
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 5 mg per mL in 1 mL vial
    • Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension
    • Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)
    Indications
    Failure or rejection of transplanted organs or tissues
  661. Tamoxifen Informations générales
    Section
    Hormones and antihormones
    • Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast
  662. Tedizolid Informations générales
    Section
    Reserve group antibiotics
    Indications
    Therapeutic equivalent to linezolid pour Methicillin resistant Staphylococcus aureus Therapeutic equivalent to linezolid pour Vancomycin resistant Staphylococcus aureus Therapeutic equivalent to linezolid pour Vancomycin resistant Enterococcus
  663. Telmisartan + amlodipine Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg
    Indications
    Essential hypertension
  664. Telmisartan + hydrochlorothiazide Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg
    Indications
    Essential hypertension
  665. Tenofovir alafenamide Informations générales
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 25 mg
    Indications
    Chronic hepatitis B
  666. Tenofovir disoproxil fumarate Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
    Indications
    Chronic hepatitis B
  667. Terbinafine Informations générales
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Cream: 1% terbinafine hydrochloride
    • Local > Topical > Ointment: 1% terbinafine hydrochloride
    Indications
    Fungal infection of the skin
  668. Terbutaline Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to salbutamol pour Chronic obstructive pulmonary disease Therapeutic equivalent to salbutamol pour Asthma
  669. Terizidone Informations générales
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to cycloserine pour Multi-drug resistant Mycobacterium tuberculosis
  670. Testosterone Informations générales
    Section
    Androgens
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)
    Indications
    Testicular dysfunction or testosterone-related disorders
  671. Tetanus antitoxin Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IM: 50000 IU in vial
    Indications
    Tetanus
  672. Tetanus vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tetanus alone
  673. Tetracaine Informations générales
    Section
    Ophthalmological preparations > Local anaesthetics
    • Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)
    Indications
    Local anaesthetics
  674. Tetracycline Informations générales
    Section
    Access group antibiotics
    • Oral > Solid: 250 mg (hydrochloride)
    Indications
    Bacterial infection of unspecified site
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)
    Indications
    Neonatal conjunctivitis or dacryocystitis Other specified conjunctivitis Infectious keratitis Infectious blepharitis Trachoma
  675. Thalidomide Informations générales
    Section
    Immunomodulators
    • Oral > Solid: 50 mg
    Indications
    Plasma cell myeloma
  676. Thiamine Informations générales
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg (hydrochloride)
    Indications
    Vitamin B1 deficiency
  677. Thiopental Informations générales
    Section
    General anaesthetics and oxygen > Injectable medicines
    Indications
    Therapeutic equivalent to propofol pour Anaesthetics and therapeutic gases
  678. Ticagrelor Informations générales
    Section
    Anti-platelet medicines
    • Oral > Solid > tablet: 60 mg; 90 mg
    Indications
    Acute ischaemic heart disease Presence of coronary angioplasty implant or graft
  679. Tick-borne encephalitis vaccine Informations générales
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against arthropod-borne viral encephalitis
  680. Tigecycline Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    Indications
    Other specified bacterial diseases
  681. Timolol Informations générales
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)
    Indications
    Primary open-angle glaucoma Ocular hypertension
  682. Tinidazole Informations générales
    Section
    Antiamoebic and antigiardiasis medicines
    Indications
    Therapeutic equivalent to metronidazole pour Amoebiasis
  683. Tioguanine Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 40 mg
    Indications
    Lymphoid leukaemia, not elsewhere classified
  684. Tiotropium bromide Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > dry powder: 18 µg capsule
    • Respiratory > Inhalation > solution: 1.25 µg per actuation; 2.5 µg per actuation
    Indications
    Chronic obstructive pulmonary disease
  685. Tisagenlecleucel Informations générales
    Section
    Antineoplastics and supportive medicines
    Indications
    Therapeutic equivalent to axicabtagene ciloleucel pour Diffuse large B-cell lymphomas
  686. Tislelizumab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 100 mg per 10 mL
    Indications
    Malignant neoplasms of urinary tract Hodgkin lymphoma Other specified malignant neoplasms of bronchus or lung
  687. Tobramycin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis
  688. Tocilizumab Informations générales
    Section
    Medicines for juvenile joint diseases
    • Parenteral > General injections > IV: 80 mg per 4 mL in vial; 200 mg per 10 mL in vial; 400 mg per 20 mL in vial
    • Parenteral > General injections > SC: 162 mg per 0.9 mL in pre-filled syringe
    Indications
    Juvenile systemic arthritis
  689. Tolbutamide Informations générales
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 500 mg
    Indications
    Type 2 diabetes mellitus
  690. Torasemide Informations générales
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to furosemide pour Heart failure
    Section
    Diuretics
    Indications
    Therapeutic equivalent to furosemide pour Anuria or oliguria Therapeutic equivalent to furosemide pour Oedema
  691. Toripalimab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 240 mg per 6 mL in vial
    Indications
    Malignant neoplasms of nasopharynx Malignant neoplasms of oesophagus
  692. Tramadol Informations générales
    Section
    Opioid analgesics
    • Oral > Liquid: 100 mg per mL (hydrochloride)
    • Oral > Solid: 50 mg (hydrochloride) immediate release; 50 mg (hydrochloride) controlled release; 100 mg (hydrochloride) controlled release; 150 mg (hydrochloride) controlled release; 200 mg (hydrochloride) controlled release; 300 mg (hydrochloride) controlled release; 400 mg (hydrochloride) controlled release
    • Parenteral > General injections > unspecified: 50 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Chronic cancer pain
  693. Trametinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 0.5 mg; 2 mg
    Indications
    Other specified melanoma of skin
  694. Tranexamic acid Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Haemorrhage, not elsewhere classified
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Postpartum haemorrhage
  695. Trastuzumab Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  696. Trastuzumab emtansine Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  697. Triamcinolone hexacetonide Informations générales
    Section
    Medicines for juvenile joint diseases
    • Parenteral > Locoregional injections > Intra-articular: 20 mg per mL in vial
    Indications
    Juvenile idiopathic arthritis
  698. Triclabendazole Informations générales
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid > tablet: 250 mg (scored)
    Indications
    Fascioliasis Paragonimiasis
  699. Trihexyphenidyl Informations générales
    Section
    Antiseizure medicines
    • Oral > Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)
    Indications
    Parkinson disease
    Section
    Medicines for parkinsonism
    Indications
    Therapeutic equivalent to biperiden pour Parkinson disease
  700. Trimethoprim Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 100 mg; 200 mg
    Indications
    Premier choix
    Infectious cystitis
  701. Triptorelin Informations générales
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin pour Malignant neoplasms of breast Therapeutic equivalent to leuprorelin pour Malignant neoplasms of prostate
  702. Tropicamide Informations générales
    Section
    Diagnostic agents > Ophthalmic medicines
    • Local > Ophthalmological > Solution (eye drops): 0.5%
    Indications
    Cycloplegic drug
  703. Tropisetron Informations générales
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron pour Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron pour Nausea or vomiting
  704. Tuberculin, purified protein derivative Informations générales
    Section
    Immunologicals > Diagnostic agents
    • Parenteral > Locoregional injections > Intradermal:
    Indications
    Mycobacterial diseases
  705. Tubocurarine Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL in 1.5 mL ampoule (tubocurarine chloride)
    Indications
    Muscle relaxants
  706. Typhoid vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against typhoid-paratyphoid alone
  707. Ulipristal Informations générales
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 30 mg tablet (ulipristal acetate)
    Indications
    Contact with health services for postcoital contraception
  708. Umeclidinium Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide pour Chronic obstructive pulmonary disease
  709. Urea Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 10%; 5%
    • Local > Topical > Ointment: 10%; 5%
    Indications
    Xerosis cutis or asteatosis
  710. Ustekinumab Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 90 mg per mL in pre-filled syringe
    Indications
    Psoriasis of unspecified type
  711. Valaciclovir Informations générales
    Section
    Antiherpes medicines
    Indications
    Therapeutic equivalent to aciclovir pour Zoster Therapeutic equivalent to aciclovir pour Varicella Therapeutic equivalent to aciclovir pour Herpes simplex infections
  712. Valganciclovir Informations générales
    Section
    Other antivirals
    • Oral > Liquid: 50 mg per mL powder for oral solution
    • Oral > Solid: 450 mg Tablet
    Indications
    Cytomegaloviral retinitis
  713. Valproic acid (sodium valproate) Informations générales
    Section
    Antiseizure medicines
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)
    • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule
    Indications
    Epilepsy or seizures Status epilepticus
    Section
    Medicines for bipolar disorders
    • Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)
    Indications
    Bipolar or related disorders
  714. Vancomycin Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
    Indications
    Premier choix
    Necrotising fasciitis co-prescrite avec ceftazidime Endophthalmitis co-prescrite avec ceftriaxone Endophthalmitis
    Second choix
    Neutropenia (high-risk)
    Autres indications
    Methicillin resistant Staphylococcus aureus
  715. Varenicline Informations générales
    Section
    Medicines for nicotine use disorders
    • Oral > Solid: 0.5 mg; 1 mg
    Indications
    Nicotine dependence
  716. Varicella vaccine Informations générales
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  717. Vecuronium Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)
    Indications
    Muscle relaxants
  718. Vemurafenib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to dabrafenib pour Other specified melanoma of skin
  719. Verapamil Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride)
    • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
    Indications
    Supraventricular tachyarrhythmia
    Section
    Antianginal medicines
    • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
    Indications
    Angina pectoris
  721. Vincristine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
    • Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Malignant trophoblastic neoplasms of placenta Follicular lymphoma Kaposi sarcoma of unspecified primary site Rhabdomyosarcoma primary site Hodgkin lymphoma Diffuse large B-cell lymphomas Retinoblastoma Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Langerhans cell histiocytosis
  722. Vinorelbine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    • Oral > Solid: 20 mg; 30 mg; 80 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast Rhabdomyosarcoma primary site
  723. Voriconazole Informations générales
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection
    • Oral > Liquid: 40 mg per mL powder for oral liquid
    • Oral > Solid: 50 mg tablet; 200 mg tablet
    Indications
    Chronic pulmonary aspergillosis Invasive aspergillosis
  724. Warfarin Informations générales
    Section
    Medicines affecting coagulation
    • Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)
    Indications
    Other specified diseases of arteries or arterioles Cerebral ischaemic stroke due to embolic occlusion Venous thromboembolism Atrial fibrillation
  725. Water for injection Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous
    • Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule
    Indications
    Unspecified appropriateness of dosing or administration without injury or harm
  726. Whole blood Informations générales
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  727. Xylometazoline Informations générales
    Section
    Ear, nose and throat medicines [c]
    • Local > Nasal > Spray: 0.05% w/v equivalent to 0.5 mg per mL
    Indications
    Nasal congestion
  728. Yellow fever vaccine Informations générales
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  730. Zidovudine Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion injection
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 250 mg capsule; 300 mg tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  731. Zinc sulfate Informations générales
    Section
    Medicines for diarrhoea
    • Oral > Solid: 20 mg
    Indications
    Diarrhoea
  732. Zoledronic acid Informations générales
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
    Indications
    Malignant neoplasm metastasis in bone or bone marrow
    Section
    Medicines for endocrine disorders
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
    Indications
    Osteogenesis imperfecta
  733. Zuclopenthixol decanoate Informations générales
    Section
    Medicines for psychotic disorders
    Indications
    Therapeutic equivalent to fluphenazine pour Schizophrenia or other primary psychotic disorders